Document:

Note Purchase Agreement and Form of Subordinated Convertible Promissory Note

 Exhibit 10.10 
 NOTE PURCHASE AGREEMENT 
 This Note Purchase Agreement, dated as of May 4, 2006, (this
“Agreement”) is entered into by and among SenoRx, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on the schedule of investors attached hereto as Schedule I (each an
“Investor” and, collectively, the “Investors”). 
 RECITALS 
 A. On the terms and subject to the conditions set forth herein, each Investor is willing to purchase from the Company, and the Company is willing to sell
to such Investor, a convertible promissory note in the principal amount set forth opposite such Investor’s name on Schedule I hereto. 
 B. Capitalized terms not otherwise defined herein shall have the meaning set forth in the form of Note (as defined below) attached hereto as Exhibit A. 
 AGREEMENT 
 NOW THEREFORE, in
consideration of the foregoing, and the representations, warranties, and conditions set forth below, the parties hereto, intending to be legally bound, hereby agree as follows: 
 1. The Notes. 
 (a) Issuance of Notes. At the Closing (as defined below), the Company agrees to issue and sell to each of the Investors, and, subject to all of the terms and conditions hereof, each of the Investors severally agrees to purchase, a
convertible promissory note in the form of Exhibit A hereto (each, a “Note” and, collectively, the “Notes”) in the principal amount set forth opposite the respective Investor’s name on
Schedule I hereto. The obligations of the Investors to purchase Notes are several and not joint. 
 (b)
Delivery. The sale and purchase of the Notes shall take place at a closing (the “Initial Closing”) to be held at such place and time as the Company and the Investors may determine (the “Initial Closing
Date”). At the Closing, the Company will deliver to each of the Investors the respective Note to be purchased by such Investor, against receipt by the Company of the corresponding purchase price set forth on Schedule I hereto (the
“Purchase Price”). Each of the Notes will be registered in such Investor’s name in the Company’s records. 
 (c) Subsequent Closing. The Company may issue additional Notes pursuant to this Agreement to such investors as it shall select, provided that the aggregate principal amount of all Notes issued pursuant to this Agreement does not
exceed $8,000,000 (each such issuance, a “Subsequent Closing” and together with the Initial Closing, the “Closing” and the date of such Subsequent Closing, the “Subsequent Closing Date” and together
with the Initial Closing Date, the “Closing Date”). At each such Subsequent Closing, the Company will deliver to each of the 

 
Investors the respective Note to be purchased by such Investor, against receipt by the Company of the respective Purchase Price through the payment of cash
as set forth on the Schedule I. Any such Investor shall become a party to this Agreement and shall have the rights and obligations hereunder. Any such Investor shall deliver the payment of the Purchase Price as set forth herein and a counterpart
signature page to this Agreement to the Company. 
 2. Representations and Warranties of the Company. The Company represents
and warrants to each Investor, except, where applicable, as set forth on the Schedule of Exceptions attached to this Agreement as Schedule II, that: 
 (a) Due Incorporation, Qualification, etc. The Company (i) is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation; (ii) has the power and
authority to own, lease and operate its properties and carry on its business as now conducted; and (iii) is duly qualified, licensed to do business and in good standing as a foreign corporation in each jurisdiction where the failure to be so
qualified or licensed could reasonably be expected to have a Material Adverse Effect. The Company has no subsidiaries. 
 (b)
Authority. The execution, delivery and performance by the Company of each Transaction Document to be executed by the Company and the consummation of the transactions contemplated thereby, including without limitation the authorization, sale,
issuance and delivery of the Notes and the shares of the Company’s capital stock issuable on conversion thereof: (i) are within the power of the Company and (ii) have been duly authorized by all necessary actions on the part of the
Company (including without limitation any necessary action on the part of the stockholders of the Company). 
 (c)
Enforceability. Each Transaction Document executed, or to be executed, by the Company has been, or will be, duly executed and delivered by the Company and constitutes, or will constitute, a legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of
equity. 
 (d) Non-Contravention. The execution and delivery by the Company of the Transaction Documents executed by
the Company and the performance and consummation of the transactions contemplated thereby, including without limitation the authorization, sale, issuance and delivery of the Notes and the shares of the Company’s capital stock issuable on
conversion thereof do not and will not (i) violate the Company’s Certificate of Incorporation or Bylaws (the “Charter Documents”) or any material judgment, order, writ, decree, statute, rule or regulation applicable to the
Company; or (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other Person to accelerate (whether after the giving of notice or lapse of time or both), any material mortgage, indenture, agreement,
instrument or contract to which the Company is a party or by which it is bound;. 
 (e) Approvals. No consent,
approval, order or authorization of, or registration, declaration or filing with, any governmental authority or other Person (including, without limitation, the shareholders of any Person) is required in connection with the execution and delivery of
the 

  

 -2- 

 
Transaction Documents executed by the Company and the performance and consummation of the transactions contemplated thereby, including without limitation the
authorization, sale, issuance and delivery of the Notes and the shares of the Company’s capital stock issuable on conversion thereof. 
 (f) Equity Securities. The Company’s total authorized and issued capitalization is as set forth in Schedule of Exceptions. The equity securities (“Equity Securities”) of the Company have
the respective rights, preferences and privileges set forth in the Company’s Charter Documents in effect on the date hereof. All of the outstanding Equity Securities of the Company have been duly authorized and are validly issued, fully paid
and nonassessable. The Company has duly reserved a sufficient number of shares of its Series C Preferred Stock and Common Stock for issuance upon conversion of the Notes and has duly reserved a sufficient number of shares of Common Stock for
issuance upon conversion of the shares of Series C Preferred Stock which may be issued upon conversion of the Notes (collectively, the “Conversion Stock”). As of the date hereof, the Company has no obligations to issue additional
equity securities or any other securities or rights convertible into equity securities except (i) as issuable pursuant to the Notes or (ii) as set forth in the fully diluted capitalization table attached to the Schedule of Exceptions. Upon
issuance in accordance with the terms of the Notes and the Company’s Certificate of Incorporation, the Conversion Stock (i) shall be duly and validly issued, fully paid and nonassessable, (ii) shall not be subject to any preemptive
rights or liens, claims, encumbrances or restrictions on transfer, other than restrictions on transfer imposed pursuant hereto or any agreement required hereunder or under applicable federal or state securities laws, and (iii) shall be issued
in compliance with all applicable securities laws, as presently in effect, of the United States and each of the states whose securities laws govern the issuance of any of the Notes hereunder. 
 (g) Litigation. There is no action, suit, proceeding or investigation pending or currently threatened against the Company which
questions the validity of this Agreement, or the Notes, or the right of the Company to enter into each such agreement, or to consummate the transactions contemplated hereby or thereby or that would have, either individually or in the aggregate, a
Material Adverse Effect. The foregoing includes, without limitation, actions pending or threatened involving the prior employment of any of the Company’s employees, the use in connection with the Company’s business of any information or
techniques allegedly proprietary to any of the Company’s former employers, or the Company’s obligations under any agreements with prior employers. The Company is not a party to, nor subject to the provisions of, any order, writ,
injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation by the Company currently pending or which the Company intends to initiate. 
 (h) Intellectual Property. The Company has sufficient title and ownership of patents, trademarks, service marks, trade names,
copyrights, trade secrets, information, proprietary rights and processes necessary for its business as now conducted and as proposed to be conducted without any known conflict with or infringement of the rights of others. There are no outstanding
options, licenses, or agreements of any kind relating to the foregoing, nor is the Company bound by or a party to any options, licenses, or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade
secrets, licenses, information, proprietary rights and processes of any other person or entity. To its knowledge after reasonable investigation, the Company has not violated nor, by conducting its business as proposed, would violate any of the

  

 -3- 

 
patents, trademarks, service marks, trade names, copyrights, or trade secrets or other proprietary rights of any other person or entity and the Company has
not received any communication alleging such a violation or alleging that the conduct of the business as proposed to be conducted, would constitute such a violation. The Company has a valuable body of trade secrets, including know-how, concepts,
computer programs and other technical data and proprietary rights and processes (the “Proprietary Information”) for the development, manufacture and sale of its products. To its knowledge after reasonable investigation, the Company
has the right to use the Proprietary Information free and clear of any rights, liens, encumbrances or claims of others, except that the possibility exists that other persons may have independently developed trade secrets or technical information
similar or identical to those of the Company. Since its formation, the Company has taken reasonable measures to protect the value (and, to the extent applicable, the confidentiality and security) of all Proprietary Information. The Company is not
aware of any such independent development nor of any misappropriation of its Proprietary Information. The Company is not aware that any of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or
other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with the use of his or her best efforts to promote the interests of the Company or that would conflict with the Company’s
business as proposed to be conducted. Neither the execution nor delivery of this Agreement or the Notes nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the Company’s business as proposed,
will, to the Company’s knowledge after reasonable investigation, conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any of such
employees is now obligated. The Company does not believe it is or will be necessary to utilize any inventions of any of its employees (or people it currently intends to hire) made prior to their employment by the Company. Set forth in
Section 2(h) of the Schedule of Exceptions is a list of all patents, trademarks and licenses of the Company. 
 (i)
Balance Sheet; Financial Statements. The Company has made available to each Investor its unaudited financial statements of December 31, 2005 and its unaudited financial statements as of February 28, 2006 (collectively, the
“Financial Statements”). The Financial Statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) applied on a consistent basis. The Financial Statements do not contain
additional financial statements and footnotes required under GAAP, and are subject to normal year-end adjustments. Except as set forth in the Financial Statements, the Company has no material liabilities, contingent or otherwise, other than
(i) liabilities incurred in the ordinary course of business subsequent to the date thereof and (ii) obligations under contracts and commitments incurred in the ordinary course of business and not required under GAAP to be reflected in the
balance sheet, which, in both cases, individually or in the aggregate are not material to the financial condition or operating results of the Company. Set forth in the Schedule of Exceptions is a list, effective as of the Closing, of all the amounts
(including amounts due for salaries or other compensation, reimbursement of expenses, advances made to or on behalf of the Company, or services rendered to or for the benefit of the Company) owed by the Company to each director and officer.

  

 -4- 

 (j) Changes. Since February 28, 2006, there has not been: 
 (i) any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the Balance
Sheet, except changes in the ordinary course of business that have not, in the aggregate, had a Material Adverse Effect; 
 (ii) any damage, destruction or loss, whether or not covered by insurance, having a Material Adverse Effect; 
 (iii)
any waiver or compromise by the Company of a material debt owed to it; 
 (iv) any satisfaction or discharge of any lien,
claim, or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and not having a Material Adverse Effect; 
 (v) any material change to a material contract or agreement by which the Company or any of its assets is bound or subject; 
 (vi) any material change in any compensation agreement or agreement with any employee, officer, director or stockholder; 
 (vii) any sale, assignment or transfer of any patents, trademarks, copyrights, trade secrets or other intangible assets; 
 (viii) any resignation or termination of employment of any officer or key employee of the Company; and the Company is not aware of any pending resignation or termination of any such officer or key employee;

 (ix) any mortgage, pledge, transfer of a security interest on or lien, created by the Company, with respect to any of its
material properties or assets, except liens for taxes not yet due or payable; 
 (x) any loans or guarantees made by the
Company to or for the benefit of its employees, officers or directors or any members of their immediate families, other than travel advances and other advances made in the ordinary course of business; 
 (xi) any declaration, setting aside or payment or other distribution in respect to any of the Company’s capital stock, or any direct
or indirect redemption, purchase, or other acquisition of any of such capital stock by the Company, except the repurchase of shares of Common Stock issued or held by employees, consultants, directors or service providers of or to the corporation or
any of its subsidiaries upon termination of their employment or services pursuant to agreements providing for the right of such repurchase between the corporation and such persons and the repurchase of shares of Common Stock in connection with the
exercise of the right of first refusal pursuant to agreements providing for the right of first refusal between the Company and any of its stockholders; 
 (xii) any material change in the accounting methods or practices followed by the Company; 
  

 -5- 

 (xiii) to the Company’s knowledge, any other event or condition that might have a
Material Adverse Effect; or 
 (xiv) any arrangement or commitment to do any of the things described in clauses
(i) –(xiii) above. 
 3. Representations and Warranties of Investors. Each Investor, for that Investor alone,
represents and warrants to the Company upon the acquisition of the Note as follows: 
 (a) Binding Obligation. Such
Investor has full legal capacity, power and authority to execute and deliver this Agreement and to perform its obligations hereunder. Each of this Agreement and the Note issued to such Investor is a valid and binding obligation of the Investor,
enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity. 
 (b) Securities Law Compliance. Such Investor has been advised that the Notes, and the underlying securities have not been
registered under the Securities Act, or any state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements is
available. Such Investor is aware that the Company is under no obligation to effect any such registration with respect to the Notes, or to file for or comply with any exemption from registration. Such Investor has not been formed solely for the
purpose of making this investment and is purchasing the Notes to be acquired by such Investor hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution
thereof. Such Investor has such knowledge and experience in financial and business matters that such Investor is capable of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment and is able to bear
the economic risk of such investment for an indefinite period of time. Such Investor is an accredited investor as such term is defined in Rule 501 of Regulation D under the Securities Act. 
 (c) Access to Information. Such Investor acknowledges that the Company has given such Investor access to the corporate records and
accounts of the Company and to all information in its possession relating to the Company, has made its officers and representatives available for interview by such Investor, and has furnished such Investor with all documents and other information
required for such Investor to make an informed decision with respect to the purchase of the Notes. 
 4. Conditions to Closing of the
Investors. Each Investor’s obligations at the Closing are subject to the fulfillment, on or prior to the Closing Date, of all of the following conditions, any of which may be waived in whole or in part by all of the Investors:

 (a) Representations and Warranties. The representations and warranties made by the Company in Section 2
hereof shall be true and correct on the Closing Date. 
  

 -6- 

 (b) Governmental Approvals and Filings. Except for any notices required or
permitted to be filed after the Closing Date with certain federal and state securities commissions, the Company shall have obtained all governmental approvals required in connection with the lawful sale and issuance of the Notes. 
 (c) Legal Requirements. At the Closing, the sale and issuance by the Company, and the purchase by the Investors, of the Notes shall
be legally permitted by all laws and regulations to which the Investors or the Company are subject. 
 (d) Proceedings and
Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and all documents and instruments incident to such transactions shall be reasonably satisfactory in substance and form to the
Investors. 
 (e) Legal Opinion. Wilson Sonsini Goodrich & Rosati, P.C. shall have provided an opinion in form
and substance reasonably satisfactory to the Investors. 
 (f) Waiver of Preemptive Rights. The Company shall have
delivered to each Investor evidence in form and substance reasonably satisfactory to such Investor evidencing the waiver of all rights of first offer or preemptive rights with respect to the Notes and the securities issuable upon conversion of the
Notes by the requisite number of investors party to the Company’s Fourth Amended and Restated Investors’ Rights Agreement, dated as of May 4, 2006, among the Company and the parties thereto. 
 5. Conditions to Obligations of the Company. The Company’s obligation to issue and sell the Notes at the Closing is subject to the
fulfillment, on or prior to the Closing Date, of the following conditions, any of which may be waived in whole or in part by the Company: 
 (a) Representations and Warranties. The representations and warranties made by the Investors in Section 3 hereof shall be true and correct on the Closing Date. 
 (b) Governmental Approvals and Filings. Except for any notices required or permitted to be filed after the Closing Date with
certain federal and state securities commissions, the Company shall have obtained all governmental approvals required in connection with the lawful sale and issuance of the Notes. 
 (c) Legal Requirements. At the Closing, the sale and issuance by the Company, and the purchase by the Investors, of the Notes shall
be legally permitted by all laws and regulations to which the Investors or the Company are subject. 
 6. Miscellaneous.

 (a) Waivers and Amendments. Any provision of this Agreement may be amended, waived or modified only upon the written
consent of the Company and Investors holding a Majority in Interest. 
 (b) Governing Law. This Agreement and all
actions arising out of or in connection with this Agreement shall be governed by and construed in accordance with the laws of 

  

 -7- 

 
the State of California, without regard to the conflicts of law provisions of the State of California or of any other state. 
 (c) Survival. The representations, warranties, covenants and agreements made herein shall survive the execution and delivery of
this Agreement. 
 (d) Successors and Assigns. Subject to the restrictions on transfer described herein, the rights and
obligations of the Company and the Investors shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties. 
 (e) Entire Agreement. This Agreement together with the other Transaction Documents constitute and contain the entire agreement
among the Company and Investors and supersede any and all prior agreements, negotiations, correspondence, understandings and communications among the parties, whether written or oral, respecting the subject matter hereof. 
 (f) Notices. All notices, requests, demands, consents, instructions or other communications required or permitted hereunder shall
in writing and faxed, mailed or delivered to each party as follows: (i) if to a Investor, at such Investor’s address or facsimile number set forth in the Schedule of Investors attached as Schedule I, or at such other address as
such Investor shall have furnished the Company in writing, or (ii) if to the Company, at 11 Columbia, Suite A, Aliso Viejo, CA 92656, facsimile: 949.362.0300, attn: Chief Executive Officer, or at such other address or facsimile number as the
Company shall have furnished to the Investors in writing. All such notices and communications will be deemed effectively given the earlier of (i) when received, (ii) when delivered, if delivered personally, (iii) when delivered, if by
facsimile (with receipt of appropriate confirmation), (iv) one business day after being deposited with an overnight courier service of recognized standing or (v) four days after being deposited in the U.S. mail, first class with postage
prepaid. 
 (g) Expenses. The Company shall pay on demand all reasonable attorneys fees and expenses of one legal
counsel to the Investors in connection with the preparation, execution and delivery of this Agreement and the other Transaction Documents, up to a maximum amount of $25,000. 
 (h) Separability of Agreements; Severability of this Agreement. The Company’s agreement with each of the Investors is a
separate agreement and the sale of the Notes to each of the Investors is a separate sale. Unless otherwise expressly provided herein, the rights of each Investor hereunder are several rights, not rights jointly held with any of the other Investors.
Any invalidity, illegality or limitation on the enforceability of the Agreement or any part thereof, by any Investor whether arising by reason of the law of the respective Investor’s domicile or otherwise, shall in no way affect or impair the
validity, legality or enforceability of this Agreement with respect to other Investors. If any provision of this Agreement shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby. 
  

 -8- 

 (i) Counterparts. This Agreement may be executed in one or more counterparts, each
of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages will be deemed binding originals. 
 (Signature Page Follows) 
  

 -9- 

 The parties have caused this Agreement to be duly executed and delivered by their proper and duly
authorized officers as of the date and year first written above. 
  

			
	COMPANY:
	
	 SENORX, INC.
 a Delaware corporation

		
	By:	 	/s/ Lloyd Malchow
	Name:	 	Lloyd Malchow
	Title:	 	President and CEO
	
	INVESTORS:
	
	MPM BIOEQUITIES MASTER FUND, LP
	
	 By: MPM BioEquities GP, L.P., its General Partner

	
	 By: MPM BioEquities GP LLC, its General Partner

		
	By:	 	/s/ Kurt Von Emster
	Name:	 	Kurt Von Emster
	Title:	 	Manager
	
	AIG ANNUITY INSURANCE COMPANY
		
	By:	 	/s/ Marc H. Gamsin
	Name:	 	  
	Title:	 	  
	
	VARIABLE ANNUITY LIFE INSURANCE COMPANY
		
	By:	 	/s/ Marc H. Gamsin
	Name:	 	  
	Title:	 	  

 [Signature page for Note Purchase Agreement] 

			
	DE NOVO VENTURES I, LP
		
	By:	 	/s/ Frederick J. Dotzler
	Name:	 	Frederick J. Dotzler
	Title:	 	Managing Director
	
	DE NOVO (Q) VENTURES I, LP
		
	By:	 	/s/ Frederick J. Dotzler
	Name:	 	Frederick J. Dotzler
	Title:	 	Managing Director

 [Signature page for Note Purchase Agreement] 

 SCHEDULE I 
 SCHEDULE OF INVESTORS 
  

				
	 Name and Address
	  	Note Amount
	 MPM BioEquities Master Fund LP
	  	$	3,000,000.00

  

	(1)	All payments on account of the Notes shall be made by bank wire transfer of immediately available funds to: 

 Chase Manhattan Bank, NY 
 New York, New York

 ABA No.: 021-000-21 
 F/A/O
Goldman Sachs & Co., NY 
 Account No.: [Intentionally Omitted] 
 Account No.: [Intentionally Omitted] 
 Account
Holder: F/F/C MPM BIOEQUITIES MASTER FUND LP 
 Reference: 
  

	(2)	Address for all notices: 

 MPM BioEquities Master Fund LP

 601 Gateway Boulevard, Suite 350 
 South San Francisco, CA 94080 
 Attn: Jake Nunn 
 Tel.:(650) 553-3350 
 Fax:(650) 553-3360 
  

 I-1 

				
	 Name and Address
	  	Note Amount
	 AIG Annuity Insurance Company
	  	$	2,000,000.00

  

	(1)	All payments on account of the Notes shall be made by bank wire transfer of immediately available funds to: 

 Bank of New York, NY 
 ABA #: 021-000-018

 AIG RS Pool 
 Account #:
[Intentionally Omitted] 
 FFC: RS2000-3 / AIG Annuity Insurance Company 
 Tax Payer Identification Number: [Intentionally Omitted] 
  

	(2)	Address for all notices: 

 AIG SunAmerica Alternative
Investments 
 1 SunAmerica Center, 38th Flr 
 Los Angeles, CA 90067 
 Attn: Troy Fukumoto 
 (310) 772-6906

 (310) 772-6705 fax 
 tfukumoto@sunamerica.com 
  

 I-2 

				
	 Name and Address
	  	Note Amount
	 Variable Annuity Life Insurance Company
	  	$	2,000,000.00

  

	(1)	All payments on account of the Notes shall be made by bank wire transfer of immediately available funds to: 

 Bank of New York, NY 
 ABA #: [Intentionally
Omitted] 
 AIG RS Pool 
 Account
#: [Intentionally Omitted] 
 FFC: RS2090-3 / Variable Annuity Life Insurance Company 
 Tax Payer Identification Number: [Intentionally Omitted] 
  

	(2)	Address for all notices: 

 AIG SunAmerica Alternative
Investments 
 1 SunAmerica Center, 38th Flr 
 Los Angeles, CA 90067 
 Attn: Troy Fukumoto 
 (310) 772-6906

 (310) 772-6705 fax 
 [Intentionally Omitted] 
  

 I-3 

				
	 Name and Address
	  	Note Amount
	 De Novo Ventures I, LP
	  	$	165,189

  

	(1)	All payments on account of the Notes shall be made by bank wire transfer of immediately available funds to: 

 [Intentionally Omitted] 
  

	(2)	Address for all notices: 

 De Novo Ventures I, LP

 1550 El Camino Real – Suite 150 
 Menlo Park, CA 94025 
 Attn: Cathy Minshall 
 Tel.:(650) 329-1999 
 Fax:(650) 329-1315 
  

 I-4 

				
	 Name and Address
	  	Note Amount
	 De Novo (Q) Ventures I, LP
	  	$	834,811

  

	(1)	All payments on account of the Notes shall be made by bank wire transfer of immediately available funds to: 

 [Intentionally Omitted] 
  

	(2)	Address for all notices: 

 De Novo (Q) Ventures I, LP

 1550 El Camino Real – Suite 150 
 Menlo Park, CA 94025 
 Attn: Cathy Minshall 
 Tel.:(650) 329-1999 
 Fax:(650) 329-1315 
  

 I-5 

 SCHEDULE II 
 CAPITALIZATION 
  

 II-1 

 EXHIBIT A 
 FORM OF NOTE 
 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION
THAT SUCH REGISTRATION IS NOT REQUIRED 
 SENORX, INC. 
 SUBORDINATED CONVERTIBLE PROMISSORY NOTE 
  

					
	$______	 		 	May 4, 2006
			
		 		 	Aliso Viejo, California

 FOR VALUE RECEIVED, SenoRx, Inc., a Delaware corporation (the “Company”) promises
to pay to _________________ (“Investor”), or its registered assigns, in lawful money of the United States of America the principal sum of
$                    , or such lesser amount as shall equal the outstanding principal amount hereof, together with interest from the date of
this Note on the unpaid principal balance at a rate equal to 15.00% per annum. All unpaid principal, together with any then unpaid and accrued interest and other amounts payable hereunder, shall be due and payable on the earlier of (i) the
date that is 19 months after the date hereof (the “Maturity Date”), or (ii) the date on which, upon or after the occurrence of an Event of Default (as defined below), such amounts are declared due and payable by the Investors.
This Note is one of the “Notes” issued pursuant to the Note Purchase Agreement of even date herewith (as amended, modified or supplemented, the “Note Purchase Agreement”) between the Company and the Investors (as defined
in the Note Purchase Agreement). 
 The following is a statement of the rights of Investor and the conditions to which this Note is subject,
and to which Investor, by the acceptance of this Note, agrees: 
 7. Definitions. As used in this Note, the following
capitalized terms have the following meanings: 
 (a) the “Company” includes the corporation initially
executing this Note and any Person which shall succeed to or assume the obligations of the Company under this Note. 
 (b)
“Event of Default” has the meaning given in Section 4 hereof. 
  

 II-1 

 (c) “Investor” shall mean the Person specified in the introductory
paragraph of this Note or any Person who shall at the time be the registered holder of this Note. 
 (d)
“IPO” shall mean the Company’s first firm commitment underwritten public offering of the Company’s Common Stock registered under the Securities Act. 
 (e) “Majority in Interest” shall mean, Investors holding more than 50% of the aggregate outstanding principal amount
of the Notes issued pursuant to the Note Purchase Agreement; provided, that a Majority in Interest must include each Investor which, individually or together with its affiliates, holds at least 33% of the aggregate outstanding principal amount of
the Notes issued pursuant to the Note Purchase Agreement. 
 (f) “Material Adverse Effect” shall mean a
material adverse effect on the business, assets, operations, prospects or financial condition of the Company. 
 (g)
“Merger” shall mean (i) the acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is party (including, without limitation, any stock acquisition,
reorganization, merger or consolidation but excluding any sale of stock for capital raising purposes) other than a transaction or series of transactions in which the holders of the voting securities of the Company outstanding immediately prior to
such transaction continue to retain (either by such voting securities remaining outstanding or by such voting securities being converted into voting securities of the surviving entity), as a result of shares in the Company held by such holders prior
to such transaction or series of transactions, at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such transaction or series of
transactions; (ii) a sale, lease or other conveyance of all or substantially all of the assets of the Company; or (iii) any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary. 
 (h) “Note Purchase Agreement” has the meaning given in the introductory paragraph hereof. 
 (i) “Obligations” shall mean and include all loans, advances, debts, liabilities and obligations, howsoever arising, owed
by the Company to Investor of every kind and description (whether or not evidenced by any note or instrument and whether or not for the payment of money), now existing or hereafter arising under or pursuant to the terms of this Note and the Note
Purchase Agreement, including, all interest, fees, charges, expenses, attorneys’ fees and costs and accountants’ fees and costs chargeable to and payable by the Company hereunder and thereunder, in each case, whether direct or indirect,
absolute or contingent, due or to become due, and whether or not arising after the commencement of a proceeding under Title 11 of the United States Code (11 U. S. C. Section 101 et seq.), as amended from time to time (including
post-petition interest) and whether or not allowed or allowable as a claim in any such proceeding. 
 (j)
“Person” shall mean and include an individual, a partnership, a corporation (including a business trust), a joint stock company, a limited liability company, an unincorporated association, a joint venture or other entity or a
governmental authority. 
  

 -2- 

 (k) “Securities Act” shall mean the Securities Act of 1933, as amended.

 (l) “Senior Indebtedness” shall mean, unless expressly subordinated to or made on a parity with the
amounts due under this Note, the principal of (and premium, if any), unpaid interest on and amounts reimbursable, fees, expenses, costs of enforcement and other amounts due in connection with, (i) indebtedness of the Company or with respect to
which the Company is a guarantor, whether outstanding on the date hereof or hereafter created, to banks, commercial finance lenders or other lending institutions regularly engaged in the business of lending money, which is for money borrowed whether
or not secured, and (ii) any deferrals, renewals or extensions or any debentures, notes or other evidence of indebtedness issued in exchange for such Senior Indebtedness. 
 (m) “Transaction Documents” shall mean this Note, each of the other Notes issued under the Note Purchase Agreement and
the Note Purchase Agreement. 
 8. Interest. If the Note is still outstanding, the accrued interest on this Note shall be
payable on the Maturity Date. 
 9. Prepayment. Except as contemplated by Section 6 below, this Note may not be
prepaid. 
 10. Events of Default. The occurrence of any of the following shall constitute an “Event of
Default” under this Note and the other Transaction Documents: 
 (a) Failure to Pay. The Company shall fail to
pay (i) when due any principal or interest payment on the due date hereunder; or (ii) any other payment required under the terms of this Note on the date due and such payment shall not have been made within five days of the
Company’s receipt of Investor’s written notice to the Company of such failure to pay; or 
 (b) Voluntary
Bankruptcy or Insolvency Proceedings. The Company shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) be unable, or admit in
writing its inability, to pay its debts generally as they mature, (iii) make a general assignment for the benefit of its or any of its creditors, (iv) be dissolved or liquidated, (v) become insolvent (as such term may be defined or
interpreted under any applicable statute), (vi) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or
hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against it, or (vii) take any action for the purpose of
effecting any of the foregoing; or 
 (c) Involuntary Bankruptcy or Insolvency Proceedings. Proceedings for the
appointment of a receiver, trustee, liquidator or custodian of the Company or of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with respect to the
Company or the debts thereof under any bankruptcy, 

  

 -3- 

 
insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered or such proceeding shall not be dismissed or
discharged within 30 days of commencement. 
 11. Rights of Investor upon Default. Upon the occurrence or existence of any
Event of Default (other than an Event of Default described in Sections 4(b) or 4(c)) and at any time thereafter during the continuance of such Event of Default, Investor may, with the consent of a majority in interest of the
holders of the Notes issued under the Note Purchase Agreement, by written notice to the Company, declare all outstanding Obligations payable by the Company hereunder to be immediately due and payable without presentment, demand, protest or any other
notice of any kind, all of which are hereby expressly waived. Upon the occurrence or existence of any Event of Default described in Sections 4(b) and 4(c), immediately and without notice, all outstanding Obligations payable by the
Company hereunder shall automatically become immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived. In addition to the foregoing remedies, upon the occurrence or
existence of any Event of Default and subject to the consent of a majority in interest of the holders of the Notes issued under the Note Purchase Agreement, Investor may exercise any other right power or remedy granted to it by the Transaction
Documents or otherwise permitted to it by law, either by suit in equity or by action at law, or both. 
 12. Conversion.

 (a) Automatic Conversion in Connection with an IPO. In the event the Company consummates an IPO prior to
November 5, 2007, then the outstanding principal amount of this Note shall automatically convert into shares of the Company’s Common Stock at a 20% discount to the public offering price of the Common Stock as stated in the final prospectus
issued in connection with the IPO. The Investor agrees to deliver the original of this Note at the closing of the IPO for cancellation, against delivery by the Company, at such closing or as soon as practicable thereafter, to Investor of the number
of shares of Common Stock to which Investor shall be entitled upon conversion of this Note pursuant to this Section 6(a); provided, however, that upon satisfaction of the conditions set forth in this Section 6(a), this
Note shall be deemed converted and of no further force and effect, whether or not it is delivered for cancellation as set forth in this sentence. The conversion shall be deemed to have been made on the closing date of such IPO. In the event of the
conversion of the principal of the Note pursuant to this Section 6(a), on the date 60 days after the date of such conversion, the Company shall pay to the Investor an amount equal to the outstanding principal amount of this Note
multiplied by 0.225. 
 (b) Optional Conversion in Connection with a Merger. In the event the Company consummates a
Merger prior to November 5, 2007, then this Note shall be convertible at the option of the Investor into that number of shares of the Company’s Series C Preferred Stock as is determined by dividing such principal amount by $1.96 per share
(adjusted to reflect subsequent stock dividends, stock splits, combinations or recapitalizations, and any other adjustments made pursuant to Article V, Section 5(c) of the Company’s Amended and Restated Certificate of Incorporation (as may
be amended from time to time)). Before Investor shall be entitled to convert this Note into shares of Series C Preferred Stock under this Section 6(b), Investor shall execute and deliver to the Company joinders to (i) the Series C
Preferred Stock Purchase Agreement dated June 28, 2001 among the Company and the parties thereto (as amended from time to time, the “Stock 

  

 -4- 

 
Purchase Agreement”) or a purchase agreement substantially identical to the Stock Purchase Agreement, (ii) the Company’s Fourth Amended
and Restated Investors’ Rights Agreement, dated as of May 3, 2006, among the Company and the parties thereto (as amended from time to time, the “Investors’ Rights Agreement”) and (iii) the Voting Agreement, dated
June 28, 2001, among the Company and the parties thereto (as amended from time to time, the “Voting Agreement”), each in a form reasonably acceptable to the Company and the Investor. In addition, before Investor shall be
entitled to convert this Note into shares of Series C Preferred Stock under this Section 6(b), it shall surrender this Note, duly endorsed, at the office of the Company and shall give written notice to the Company at its principal
corporate office, of the election to convert the same pursuant to this Section. The Company shall, as soon as practicable thereafter, take all action necessary to execute and deliver to the Investor counterparts to the joinders to the Stock Purchase
Agreement, Investors’ Rights Agreement and Voting Agreement executed by the Investor, and issue and deliver at such office to Investor a certificate or certificates for the number of shares of Series C Preferred Stock to which Investor shall be
entitled upon conversion (bearing such legends as are required by the Series C Preferred Stock purchase agreement, the Note Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to the Company). The conversion
shall be deemed to have been made immediately prior to the close of the Merger. In the event of the conversion of the principal of the Note pursuant to this Section 6(b), on the date 60 days after the date of such conversion, the Company
shall pay to the Investor an amount equal to the outstanding principal amount of this Note multiplied by 0.225. In the event the Investor chooses not to convert this Note pursuant to this Section 6(b), the outstanding principal and
accrued interest of this Note shall due and payable on the closing of the Merger. In the event any such Merger does not close, this Note shall remain outstanding in accordance with the terms set forth herein. 
 (c) Automatic Conversion into Series C Preferred Stock. If the this Note is still outstanding on November 5, 2007, then the
outstanding principal amount of this Note plus an additional amount equal to the outstanding principal amount of this Note multiplied by 0.225 (the “Total Amount”) shall automatically convert into that number of shares of the
Company’s Series C Preferred Stock as is determined by dividing such Total Amount by $1.96 per share (adjusted to reflect subsequent stock dividends, stock splits, combinations or recapitalizations, and any other adjustments made pursuant to
Article V, Section 5(c) of the Company’s Amended and Restated Certificate of Incorporation (as may be amended from time to time)). Before Investor shall be entitled to convert this Note into shares of Series C Preferred Stock under this
Section 6(c), the Investor shall execute and deliver to the Company joinders to (i) the Stock Purchase Agreement or a purchase agreement substantially identical to the Stock Purchase Agreement, (ii) Company’s
Investors’ Rights Agreement and (iii) the Voting Agreement, each in a form reasonably acceptable to the Company and the Investor. In addition, before Investor shall be entitled to convert this Note into shares of Series C Preferred Stock
under this Section 6(c), it shall surrender this Note, duly endorsed, at the office of the Company and shall give written notice to the Company at its principal corporate office, of the election to convert the same pursuant to this
Section. The Company shall, as soon as practicable thereafter, take all action necessary to execute and deliver to the Investor counterparts to the joinders to the Stock Purchase Agreement, Investors’ Rights Agreement and Voting Agreement
executed by the Investor, and issue and deliver at such office to Investor a certificate or certificates for the number of shares of Series C Preferred Stock to which Investor shall be entitled upon conversion (bearing such legends as are required
by the Series C Preferred Stock 

  

 -5- 

 
purchase agreement, the Note Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to the Company). 
 (d) Optional Conversion prior to Private Placement. In the event the Company intends to enter into a venture capital, institutional
or other equity financing primarily for the purpose of raising capital for the account of the Company in which shares of the Company’s preferred stock are issued (a “Private Placement”) prior to November 5, 2007, the
Company shall provide Investor with no less than 30 days’ prior written notice of such Private Placement (the “Private Placement Notice”), which Private Placement Notice shall be accompanied by drafts of all documents intended
to be executed in connection therewith. Upon receipt of the Private Placement Notice, the principal amount outstanding under this Note shall be convertible at the option of the Investor into that number of shares of the Company’s Series C
Preferred Stock as is determined by dividing such principal amount by $1.96 per share (adjusted to reflect subsequent stock dividends, stock splits, combinations or recapitalizations, and any other adjustments made pursuant to Article V,
Section 5(c) of the Company’s Amended and Restated Certificate of Incorporation (as may be amended from time to time)). Investor must give notice to Company within twenty (20) days of the date of receipt of the Private Placement
Notice in order for the Note to be convertible under this Section 6(d). Before Investor shall be entitled to convert this Note into shares of Series C Preferred Stock under this Section 6(d), Investor shall execute and
deliver to the Company joinders to (i) the Stock Purchase Agreement or a purchase agreement substantially identical to the Stock Purchase Agreement, (ii) Company’s Investors’ Rights Agreement and (iii) the Voting Agreement,
each in a form reasonably acceptable to the Company and the Investor. In addition, before Investor shall be entitled to convert the principal amount of this Note into shares of Series C Preferred Stock under this Section 6(d), it shall
surrender this Note, duly endorsed, at the office of the Company and shall give written notice to the Company at its principal corporate office, of the election to convert the same pursuant to this Section. The Company shall, as soon as practicable
thereafter, take all action necessary to execute and deliver to the Investor counterparts to the joinders to the Stock Purchase Agreement, Investors’ Rights Agreement and Voting Agreement executed by the Investor, and issue and deliver at such
office to Investor a certificate or certificates for the number of shares of Series C Preferred Stock to which Investor shall be entitled upon conversion (bearing such legends as are required by the Series C Preferred Stock purchase agreement, the
Note Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to the Company). The conversion shall be deemed to have been made immediately prior to the close of the Private Placement, provided that Investor
shall be entitled, but not obligated, to participate in the Private Placement pursuant to Section 5 of the Investors’ Rights Agreement as if Investor was an “Investor” (as defined thereunder) that is entitled to the right of
first offer provided for in Section 5 thereof, and Investor’s pro rata share for purposes of Section 5 thereof shall be determined assuming that the principal amount of this Note has been converted into Series C Preferred Stock
pursuant to this Section 6(d). In the event of the conversion of the principal of the Note pursuant to this Section 6(d), on the date 60 days after the date of such conversion, the Company shall pay to the Investor an amount
equal to the outstanding principal amount of this Note multiplied by 0.225. In the event any such Private Placement does not close, this Note shall remain outstanding in accordance with the terms set forth herein. 
  

 -6- 

 (e) Fractional Shares; Interest; Effect of Conversion. No fractional shares shall
be issued upon conversion of this Note. Instead, the Company shall round down the number of shares issued upon conversion of this Note. 
 13. Successors and Assigns. Subject to the restrictions on transfer described in Sections 9 and 10 below, the rights and obligations of the Company and Investor shall be binding upon and benefit the
successors, assigns, heirs, administrators and transferees of the parties. 
 14. Waiver and Amendment. Any provision of
this Note may be amended, waived or modified upon the written consent of the Company and the holders of a Majority in Interest. 
 15.
Transfer of this Note or Securities Issuable on Conversion Hereof. Prior to any proposed sale, assignment, transfer or pledge of this Note or any securities into which such Note may be converted (collectively,
“Conversion Securities” and, together with the Notes, collectively referred to herein as “Restricted Securities”), (other than (i) a transfer not involving a change in beneficial ownership, or (ii) in
transactions involving the distribution without consideration of Restricted Securities by any holder or Investor to any of its partners, members or retired partners or members, or to the estate of any of its partners, members or retired partners or
members, (iii) a transfer to an affiliated fund, partnership or company, which is not a competitor of the Company, subject to compliance with applicable securities laws, or (iv) transfers in compliance with Rule 144, so long as the Company
is furnished with satisfactory evidence of compliance with such Rule), unless there is in effect a registration statement under the Securities Act covering the proposed transfer, the holder thereof shall give written notice to the Company of such
holder’s intention to effect such transfer, sale, assignment or pledge. Each such notice shall describe the manner and circumstances of the proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied, if
requested by the Company, at such holder’s expense by either (i) a written opinion addressed to the Company of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company addressed to the Company, to
the effect that the proposed transfer of the Restricted Securities may be effected without registration under the Securities Act, or (ii) a “no action” letter from the Commission to the effect that the transfer of such securities
without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in
accordance with the terms of the notice delivered by the holder to the Company. Each certificate evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to Rule 144, appropriate
restrictive legends, except that such certificate shall not bear such restrictive legend if in the opinion of counsel for such holder and in the reasonable opinion of the Company such legend is not required in order to establish compliance with any
provision of the Securities Act. 
 Subject to the foregoing, transfers of this Note shall be registered upon registration books maintained for such purpose
by or on behalf of the Company. Prior to presentation of this Note for registration of transfer, the Company shall treat the registered holder hereof as the owner and holder of this Note for the purpose of receiving all payments of principal and
interest hereon and for all other purposes whatsoever, whether or not this Note shall be overdue and the Company shall not be affected by notice to the contrary. Notwithstanding the foregoing, this Note may not be transferred to a competitor, as
determined in good faith by the Company’s Board of Directors, of the Company. 
  

 -7- 

 16. Assignment by the Company. Neither this Note nor any of the rights, interests or
obligations hereunder may be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior written consent of the holders of a Majority in Interest. 
 17. Notices. All notices, requests, demands, consents, instructions or other communications required or permitted hereunder shall in
writing and faxed, mailed or delivered to each party at the respective addresses of the parties as set forth in the Note Purchase Agreement, or at such other address or facsimile number as the Company shall have furnished to Investor in writing. All
such notices and communications will be deemed effectively given on the earlier of (i) when received, (ii) when delivered, if delivered personally, (iii) when delivered if by facsimile (with receipt of appropriate confirmation),
(iv) one business day after being deposited with an overnight courier service of recognized standing or (v) four days after being deposited in the U.S. mail, first class with postage prepaid. The Company shall give Investor at least 20
days’ prior written notice of the closing of any Merger. 
 18. Standoff Agreement. Each Investor agrees, in
connection with the Company’s initial public offering of the Company’s securities, upon request of the Company or the underwriters managing any underwritten offering of the Company’s securities, (i) not to sell, make any short
sale of, loan, grant any option for the purchase of, or otherwise dispose of any Common Stock (or other securities) of the Company issued pursuant to this Note or the Note Purchase Agreement (other than those included in the registration, if any)
without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days or such other period as may be requested by the Company or an underwriter to
accommodate regulatory restrictions) from the effective date of such registration as may be requested by the underwriters; provided, that the officers, directors and one percent (1%) security holders of the Company who own stock of the
Company also agree to such restrictions on the same terms and conditions and (ii) to execute any agreement reflecting (i) above as may be requested by the underwriters at the time of the initial public offering. 
 19. Subordination. The indebtedness evidenced by this Note is hereby expressly subordinated, to the extent and in the manner hereinafter
set forth, in right of payment to the prior payment in full of all of Company’s Senior Indebtedness. 
 Upon any receivership,
insolvency, assignment for the benefit of creditors, bankruptcy, reorganization, or arrangement which creditors (whether or not pursuant to bankruptcy or other insolvency laws), sale of all or substantially all of the assets, dissolution,
liquidation, or any other marshaling of the assets and liabilities of the Company or in the event this Note shall be declared due and payable, (i) no amount shall be paid by the Company, whether in cash or property in respect of the principal
of or interest on this Note at the time outstanding, unless and until the full amount of any Senior Indebtedness then outstanding shall be paid in full, and (ii) no claim or proof of claim shall be filed with the Company by or on behalf of the
holder of this Note which shall assert any right to receive any payments in respect of the principal of and interest on this Note except subject to the payment in full all of the Senior Indebtedness then outstanding. 
 If an event of default has occurred with respect to any Senior Indebtedness, permitting the holder thereof to accelerate the maturity thereof, then
unless and until such event of default shall 

  

 -8- 

 
have been cured or waived or shall have ceased to exist, or all Senior Indebtedness shall have been paid in full, no payment shall be made in respect of the
principal of or interest on this Note. 
 Nothing contained in this the preceding paragraphs shall impair, as between the Company and the
Investor, the obligation of the Company, which is absolute and unconditional, to pay to the Investor hereof the principal hereof and interest hereon as and when the same shall become due and payable, or shall prevent the Investor, upon default
hereunder, from exercising all rights, powers and remedies otherwise provided herein or by applicable law, all subject to the rights, if any, of the holders of Senior Indebtedness under the preceding paragraphs to receive cash or other properties
otherwise payable or deliverable to the Investor pursuant to this Note. 
 20. Action to Collect on Note. If action is
instituted to collect on this Note, the Company promises to pay all costs and expenses, including reasonable attorney’s fees, incurred in connection with such action. 
 21. Loss of Note. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Note or
any Note exchanged for it, and indemnity satisfactory to the Company (in case of loss, theft or destruction) or surrender and cancellation of such Note (in the case of mutilation), the Company will make and deliver in lieu of such Note a new Note of
like tenor. 
 22. Governing Law. This Note and all actions arising out of or in connection with this Note shall be
governed by and construed in accordance with the laws of the State of California, without regard to the conflicts of law provisions of the State of California, or of any other state. 
 (Signature Page Follows) 
  

 -9- 

 The Company has caused this Note to be issued as of the date first written above. 
  

			
	 SENORX, INC.
 a Delaware
corporation

		
	By:	 	  
	Name:	 	  
	Title:Vacuum Assisted Breast Biopsy Agreement

 Exhibit 10.11 
 CONTRACT NO. KP-604 
 AGREEMENT FOR 
 VACUUM ASSISTED BREAST BIOPSY 
 NEEDLE, SYSTEM, AND ACCESSORY 
 PRODUCTS 
 between 
 KP SELECT, INC. 
 and 
 SENORX, INC. 
 DATED: April 1, 2005 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 This Agreement for Vacuum Assisted Breast Biopsy Needle, System, and Accessory Products (the
“Agreement”), effective as of April 1, 2005 (the “Effective Date”), is between KP Select, Inc., a Delaware corporation with offices at 13727 Noel Road, Suite 1400, Dallas, Texas 75240 (“KPS”), and SenoRx, Inc., a Delaware corporation with offices at 11 Columbia, Aliso Viejo, California 92656
(“Supplier”). 
 KPS operates a group-purchasing program through which KPS negotiates contracts for certain Products on behalf of
health care providers (including hospitals, physician offices, nursing homes, ambulatory surgery centers, home care agencies, diagnostic imaging centers, long-term care facilities, etc.) that designate KPS as their group-purchasing agent (the
“Customers”). Customer also includes a parent corporation of a health care provider or third party agent that enters into an agreement with KPS designating KPS as the purchasing agent of the health care provider. 
 Supplier is a vendor of the products and related services listed on Exhibit A (the “Products”) and desires to enter into this Agreement
to allow the Customers to purchase the Products. 
 In consideration of the mutual conditions and agreements set forth in this Agreement, and
for good and valuable consideration, the adequacy and receipt of which are acknowledged. KPS and Supplier agree that Supplier shall provide Products to Customers under the following terms and conditions: 
 SECTION 1 
 TERM OF AGREEMENT

 This Agreement remains in effect for a period of three years, commencing on the Effective Date and expiring on March 31, 2008
(the “Term”), unless terminated earlier or extended later as provided in this Agreement. 
 SECTION 2 
 PARTICIPATION 
 2.1 Qualification for
Participation. Customers (including entities that become Customers after the Effective Date) may purchase Products pursuant to the terms of this Agreement. Any Customer that withdraws or is terminated as a Customer may not purchase Products
pursuant to the terms of this Agreement. 
 2.2 List of KPS Customers. KPS shall provide Supplier with a list of Customers (in electronic
format) as of the Effective Date, and shall provide regular updates. 
 2.3 Termination of Existing Contracts. Any Customer that wishes to
purchase Products under this Agreement may, at its option and without any penalty or cost, terminate any existing 

  

					
	 SenoRx. Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	1	  	

 
contract or other arrangement with Supplier for the same Products. Supplier shall not directly or indirectly contract with any Customer for Products.

 2.4 Responsibility and Liability. Each Customer is liable directly to Supplier for all payments and any other obligations with respect to Products.
Supplier is solely responsible for invoicing Customers for Products. Except as set forth in this Agreement, KPS has no liability, responsibility, or performance obligations to Supplier relating to any Products. 
 SECTION 3 
 PRICING, ORDERING, AND
DELIVERY 
 3.1 Pricing and Payment. 
 3.1.1 Firm Pricing. The prices for each of the Products that Supplier offers for sale to Customers under this Agreement are set forth on Exhibit A. Supplier shall not increase these prices during the Term. Supplier must not
invoice Customer for any charges not identified on Exhibit A: for example, Supplier must not charge Customer for any shipping or freight charges, late fees, or for any other fees or surcharges. The Product systems identified on Exhibit
A (each a “Product System”) are a subset of Products. 
 3.1.2 Pricing and Other Data. Supplier shall provide KPS with
pricing information in an EDI 832 equivalent format, or in Excel format set forth under Section I of Exhibit B. KPS and Supplier shall mutually agree upon the method of transmission of this pricing data. In addition, Supplier shall provide
the cross-reference file layout, product attributes file layout, and product categorization file layout information set forth in Sections II, III, and IV of Exhibit B. 
 3.1.3 Pricing on New Products. If Supplier begins to sell a similar product not listed on Exhibit A, Supplier shall notify KPS and each
Customer within 30 days of governmental approval or Supplier’s release of the product. KPS and Supplier shall promptly amend Exhibit A to add the new Product(s) at a mutually agreed upon price. 
 3.1.4 Favorable Pricing. The prices, terms, and conditions under this Agreement must be equal to or better than those offered to any other
customer of Supplier. If Supplier is not in compliance, KPS and Supplier shall amend this Agreement to provide the more favorable terms. 
 3.1.5 Market Price. If KPS determines that (a) there occurred a material change in the market affecting a Product, and (b) that market change resulted in a market price for that Product that is lower than the price set
forth on Exhibit A; then, upon notice from KPS, Supplier must offer new pricing for that Product that is no greater than the new market price within 30 days after receiving KPS’ notice. 
 3.2 Distribution. If any Products are purchased through an authorized distributor, all taxes, ordering, and delivery terms are governed by the applicable terms of
the Customer’s agreement with the distributor. 
  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	2	  	

 3.3 Taxes on Direct Purchases. Supplier shall calculate and pay any applicable local and state sales tax or other
taxes with respect to the direct purchase of Products. Unless the applicable Customer is tax-exempt, these taxes may be billed to the Customer if correctly and accurately reflected on the invoice. 
 3.4 Ordering and Delivery for Direct Purchases. 
 3.4.1 Purchase Orders. Customer may place purchase orders for Products by telephone, fax, or through electronic order entry directly through Supplier at: 
 SenoRx, Inc. 
 11 Columbia 
 Aliso Viejo, California 92656 
 Telephone No.: 949.362.4800 
 Fax No.: 949.362.3519 
 www.senorx.com

 There are no minimum order requirements for Products, however orders may only be placed in Supplier’s standard sale unit of measure.

 3.4.2 Payment. Payments for Products are due from Customers within [***] of receipt of the invoice. Supplier must accept any
commercially reasonable form of payment from Customer, including payment by Customer’s credit card or procurement card. 
 3.4.3
Delivery. All Products must be delivered to the Customer’s place of business or any other location specified by Customer not more than [***] after Supplier’s receipt of the Customer’s order for Product. All prices set forth on
Exhibit A include shipping (all Product purchases are F.O.B. Destination). Upon Customer’s written request, Supplier will ship Products “freight collect” to Customer using the carrier and billing information provided by
Customer. If Customer orders overnight delivery of any Product, Supplier must prepay all shipping charges, but Supplier may charge Customer for the difference between the Supplier’s cost for standard shipping of the Product and Supplier’s
cost for overnight delivery of the Product, if Supplier correctly sets forth the shipping cost difference as a separate line item on Supplier’s invoice to Customer. If Supplier fails for any reason to ship the Product within the applicable
timeframe, then Supplier must (a) ship the Product via overnight delivery service as soon as the Product is available to ship, and (b) prepay all shipping charges (and Supplier must not charge Customer any amount for shipping the Product
via overnight delivery service). The risk of loss of the Products does not pass to the Customer until the Customer accepts the Products. 
 3.4.4 Failure to Supply. In the event Supplier fails to perform its obligations under this Section, Customer may purchase comparable products from another source with prior authorization from Supplier. Supplier will remit the
difference between the price of the contracted Product as shown on Exhibit A and the comparable product to the Customer within 30 days of receiving documentation of the amount. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	3	  	

 3.4.5 Returns. Customers may return Products sold by Supplier in accordance with Supplier’s
return policy, set forth on Exhibit C. 
 SECTION 4 
 ADMINISTRATIVE FEES 
 4.1 Calculation of Administrative Fees. On a monthly basis,
Supplier shall pay KPS a fee (the “Administrative Fee”) equal to [***] of the aggregate purchase price for all Products purchased by all Customers during the prior calendar month, less any credits and returns. Supplier shall pay the
Administrative Fee no later than 30 days after the end of each applicable calendar month. 
 4.2 Rebates. If Supplier owes any rebates to any Customer
under this Agreement (whether payable directly to the Customer or through KPS to the Customer), Supplier shall provide KPS with a report of the rebates in the format detailed in Exhibit D. 
 4.3 Monthly Reporting. Accompanying the Administrative Fee payment or any rebate payment, if applicable, Supplier shall provide KPS with monthly reports of all
Products purchased by each Customer. Each report must include: (i) the start and end dates of the reporting period; (ii) each Customer’s name, address, and HIN or DEA number or both (as provided on a KPS Customer list);
(iii) KPS’ contract number; (iv) sales volume per contract (subtotaled by Customer) for the reporting period; and (v) the Administrative Fees earned by KPS during the month (subtotaled by Customer). Supplier must send all monthly
reporting documentation in the electronic format as detailed in Exhibit D or via KPS’ proprietary reporting software solution (“SSRS”). If Supplier chooses to use the SSRS solution, it must execute the licensing agreement and
pay any applicable data integrity fees. Supplier must pay KPS its hourly fee for KPS to re-format the data Supplier sends in any format not listed here. 
 SECTION 5 
 TERMINATION 
 5.1 Termination for Breach or Ineligibility. In the event of a material breach of this Agreement (including any failure to pay Administrative Fees), the non-breaching party shall notify the breaching party in
writing of the specific breach and shall request that it be cured. If the breaching party does not cure the breach within 30 days of the notice, the non-breaching party may terminate this Agreement by sending written notice to the breaching party.
KPS may immediately terminate this Agreement if Supplier or any of Supplier’s key personnel is convicted of an offense related to health care or listed by a federal agency as being debarred, excluded, or otherwise ineligible for federal program
participation. 
 5.2 KPS’ Right to Terminate For Convenience. Without cost or penalty, KPS may terminate this Agreement for any reason or
no reason by providing 30 days’ advance notice to Supplier. This termination right is in addition to any other termination rights in this Agreement. 
  

					
	 SenoRx. Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	4	  	

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 This provision (5.2 KPS’ Right to Terminate for Convenience) does not confer any right for Supplier to terminate the
Agreement. 
 5.3 Effect of Termination. The termination of the Agreement by either party does not excuse either party from performing any duty or
obligation assumed under the Agreement before termination, nor does termination have the effect of waiving any right either party may have to obtain performance or preclude the non-breaching party from pursuing any and all remedies available to it
at law or equity. 
 SECTION 6 
 MISCELLANEOUS 
 6.1 KPS’ Standard Terms and Conditions. KPS’ Standard Terms and Conditions are attached as Exhibit
E. 
 6.2 Product Specific Terms and Conditions. Additional Terms and Conditions related to the specific Products covered by this Agreement are
attached as Exhibit F. 
 6.3 Environmental and Social Issues. Additional terms are attached as Exhibit H Supplier shall make disclosure
required by Exhibit H within a reasonable time after the Effective Date unless Supplier has submitted a disclosure within the last 12 months and that disclosure remains substantially accurate. 
 6.4 Quality Assessment and Improvement Programs. Customer’s description of its Quality Assessment and Improvement Programs, as well as Customer’s
compliance objectives with regard to JCAHO standards, federal and state regulations, and laws are set forth on Exhibit I. 
 6.5 Implementation
plan. A material term in this Agreement is that Supplier must install Product Systems in Customers’ facilities according to certain pre-determined schedules, and at no additional cost to Customers. If Supplier fails to install Product
Systems according to these schedules, it will cause significant damages to Customer. 
 Customer has the sole right to designate the order of locations that
Supplier installs Product Systems into. Customer may alter the schedule and may slow down the installation pace at its sole discretion, without cost or penalty. 
 The services that Supplier must provide as part of its implementation, and the schedule for providing those implementation services are described on Exhibit J. 
 6.6 Maintenance Policy. Supplier’s policy for Product maintenance is set forth on Exhibit K. If requested by KPS or Customer, Supplier must provide a description of Supplier’s maintenance
capabilities including Supplier’s local and regional factory-based service capabilities, the number and individual qualifications of Supplier’s service engineers (including backup service engineers), approximate response time for emergency
repairs (both during regular business hours and during hours outside of regular business hours), the location of and 

  

					
	 SenoRx. Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	5	  	

 
approximate delivery time for primary and backup spare parts, and a description of Supplier’s factory engineering backup capabilities. 
 6.7 Trade-in Allowances. The trade-in allowances for used systems that Supplier must offer to each Customer (and that Customer may apply to the purchase of any
new Product System) are set forth on Exhibit L. Supplier must mail a copy of any quotation involving, a trade-in allowance to KPS. 
 6.8 Business
Continuity/Disaster Plan. As a supplier to the healthcare industry, Supplier realizes the importance of healthcare delivery during disasters. Supplier shall have a written business continuity/disaster recovery plan, for which Supplier will
maintain and test all critical components on a regular basis. At the request of Customer, Supplier must provide to Customer proof of this plan. 
 6.9
Controlling Terms. In the event of a conflict between this Agreement and any other writing or correspondence between Supplier, KPS, and/or any Customer, the terms of this Agreement control. In the event of any internal conflict of terms within
this Agreement, the term found in the part of this Agreement first listed below controls: the main body of the Agreement; Exhibit E (KPS’ Standard Terms and Conditions); Exhibit F (Standard Terms and Conditions – Products and
Product Systems); Exhibit A (Products and Pricing); Exhibit L (Trade-in Allowances); Exhibit B (KPS Pricing Requirements); Exhibit D (Sales Data Report Format); Exhibit C (Supplier’s Return Policy); Exhibit
G (Supplier’s Product Warranties); Exhibit J (Implementation Plan); Exhibit K (Maintenance Policy); Exhibit H (Supplier’s Environmental and Social Issues Disclosures); Exhibit I (Quality Assessment and
Improvement Programs); any other exhibits provided to KPS by Supplier. 
 6.10 Entire Agreement. This Agreement may be executed in any number of
counterparts, each of which is deemed an original but all of which constitute the same instrument. This Agreement, including all exhibits and attachments (all of which are incorporated in this Agreement by reference), constitutes the entire
agreement on this subject and supersedes all previous and contemporaneous communications, representations, or agreements regarding the referenced subject matter. In the event of a conflict between this Agreement and any other writing or
correspondence between Supplier, KPS, and/or any Customer, the terms of this Agreement control. This Agreement may not be modified orally, and no modification, amendment, or supplement is binding unless it is in writing and signed by authorized
representatives of KPS and Supplier. 
  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	6	  	

 The undersigned duly authorized representatives of the parties have executed this Agreement as of the
date written below. 
  

									
	KP SELECT, INC.	 		 	SENORX, INC.
					
	By:	 	 /s/ DeAnna Herrin
	 		 	By:	 	/s/ William F. Gearhart
					
	Printed Name:	 	DeAnna Herrin	 		 	Printed Name:	 	William F. Gearhart
				
	KPS Contracting Services	 		 	 Its:
	 	Vice President
					
	Date:	 	2/17/05	 		 	Date:	 	2/17/05

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	7	  	

 EXHIBIT A 
 PRODUCTS AND PRICING 
 (attached) 
  

					
	 SenoRx. Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	8	  	

 Ex. A 
 Products and Pricing 
 Breast Biopsy Disposables 
  

													
	 Catalog Number
	 	 Product Description
	 	Qty/UOM	 	UOM	 	List Price	 	Contract Price
	 ST CLIP Package
	 	ST Package: Needle, Guide, Tubing, Cannister, Clip	 	1	 	EA	 	$	[***]	 	$	[***]
	 US CLIP Package
	 	US Package: Needle, Tubing, Cannister, Clip	 	1	 	EA	 	$	[***]	 	$	[***]
	 ST Package
	 	ST Package: Needle, Guide, Tubing, Cannister	 	1	 	EA	 	$	[***]	 	$	[***]
	 US Package
	 	US Package: Needle, Tubing, Cannister	 	1	 	EA	 	$	[***]	 	$	[***]
	 ECP01-10G
	 	EnCor Stereotactic/Ultrasound Probe, 10 gauge (sterile tubing included)	 	1	 	EA	 	$	[***]	 	$	[***]
	 ECP01-7G
	 	EnCor Stereotactic/Ultrasound Probe, 7 gauge (sterile tubing included)	 	1	 	EA	 	$	[***]	 	$	[***]
	 ECPMR01
	 	EnCor MRI Probe & Introducer	 	1	 	EA	 	$	[***]	 	$	[***]
	 GMUEC011T
	 	Marker Clip Gel Mark for EnCor titanium	 	1	 	EA	 	$	[***]	 	$	[***]
	 GMUEC011
	 	Marker Clip Gel Mark for EnCor stainless	 	1	 	EA	 	$	[***]	 	$	[***]
	 GMUECMRT
	 	Marker Clip Gal Mark EnCor MRI titanium	 	1	 	EA	 	$	[***]	 	$	[***]
	 GMUECMR
	 	Marker Clip Gel Mark EnCor MRI stainless	 	1	 	EA	 	$	[***]	 	$	[***]
	 GMUTC005T
	 	Marker Clip UltraCor for 14G titanium	 	1	 	EA	 	$	[***]	 	$	[***]
	 GMUTC005
	 	Marker Clip UltraCor for 14G stainless steel	 	1	 	EA	 	$	[***]	 	$	[***]
	 GMUTCMRI
	 	Marker Clip Gel Mark UltraCor MRI	 	1	 	EA	 	$	[***]	 	$	[***]
	 GMUTCMRIT
	 	Marker Clip Gel Mark UltraCor MRI & Intro.	 	1	 	EA	 	$	[***]	 	$	[***]
	 DR ENCOR
	 	EnCor Biopsy Driver	 	1	 	EA	 	$	[***]	 	$	[***]
	 DR ENCOR MR
	 	EnCor MRI Biopsy Driver	 	1	 	EA	 	$	[***]	 	$	[***]
	 SCTUB3000
	 	Tubing Set (each price) SCTUB3000 Non-sterile Tubing for Vacuum Canister (1 per day usage)	 	1	 	EA	 	$	[***]	 	$	[***]
	 SCCAN01
	 	1200cc Canister (each price) SCCAN01 EnCor Canister (1200cc)	 	1	 	EA	 	$	[***]	 	$	[***]
	 ENCINSERT01
	 	Guide (each price) ENCINSERT (for Fischer and Lorad)	 	1	 	EA	 	$	[***]	 	$	[***]
	
	Breast Biopsy Instruments
						
	 Catalog Number
	 	 Product Description
	 	Qty/UOM	 	UOM	 	List Price	 	Contract Price
	ENCYSYS-US	 	ENCYSYS-US EnCor Ultrasound System (Include Vacuum System, Control Module, EnCor Biopsy Driver, Foot Pedal, Carl, Cup Holder)	 	1	 	EA	 	$	[***]	 	$	[***]
	ENCYSYS-ST	 	ENCYSYS-ST EnCor Stereotactic System (Include Vacuum System, Control Module, Driver, Foot Pedal, Cart, Cup Holder, Fire Forward for Fischer of Lorad)	 	1	 	EA	 	$	[***]	 	$	[***]
	ENCYSYS-MR	 	ENCYSYS-MR EnCor MRI System (Includes Vacuum System, Control Module, Driver, Fool Pedal, Cart, Cup Holder, MRI Driver)	 	1	 	EA	 	$	[***]	 	$	[***]
	ENCYSYS-ST/MR	 	ENCYSYS-ST/MR EnCor Stereo System with additional MRI Driver	 	1	 	EA	 	$	[***]	 	$	[***]
	ENCYSYS-US SUPPLEMENT	 	ENCYSYS-US EnCor Ultrasound System (Include Vacuum System, Control Module, EnCor Biopsy Driver, Foot Pedal, Cart, Cup Holder)	 	1	 	EA	 	$	[***]	 	$	[***]
	ENCYSYS-ST SUPPLEMENT	 	ENCYSYS-ST EnCor Stereotactic System (Include Vacuum
System, Control Module, Driver, Foot Pedal, Cart, Cup Holder, Fire Forward for Fischer or Lorad)	 	1	 	EA	 	$	[***]	 	$	[***]
	ENCYSYS-MR SUPPLEMENT	 	ENCYSYS-MR EnCor MR System (Includes Vacuum System, Control Module, Driver, Foot Pedal, Cart, Cup Holder, MRI Driver)	 	1	 	EA	 	$	[***]	 	$	[***]
	ENCYSYS-ST/MR SUPPLEMENT	 	ENCYSYS-ST/MR EnCor Stereo System with additional MRI Driver	 	1	 	EA	 	$	[***]	 	$	[***]
	
	Warranties/Repairs
						
	 Catalog Number
	 	 Product Description
	 	Qty/UOM	 	UOM	 	List Price	 	Contract Price
	 MINOR REPAIR
	 	Minor Repair for out of warranty console	 	1	 	EA	 	$	[***]	 	$	[***]
	 MAJOR REPAIR
	 	Major Repair for out of warranty console	 	1	 	EA	 	$	[***]	 	$	[***]
	 LOANER UNIT
	 	Loaner unit for out of warranty console	 	1	 	EA	 	$	[***]	 	$	[***]
	 WARRANTY 1 YEAR
	 	1 year extended warranty	 	1	 	EA	 	$	[***]	 	$	[***]
	 WARRANTY 2 YEAR
	 	2 year extended warranty	 	1	 	EA	 	$	[***]	 	$	[***]
	 WARRANTY 3 YEAR
	 	3 year extended warranty	 	1	 	EA	 	$	[***]	 	$	[***]

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 1 of 1 

 EXHIBIT B 
 KPS PRICING REQUIREMENTS 
  

			
	 I.      CONTRACT PRICING
	  	
		
	 A.     REQUIRED FORMAT.
	  	ASCII TAB Delimited file.
		
	 B.     REPORTING FREQUENCY.
	  	Supplier to provide initial contract pricing data at least 30 days prior to the Effective Date and shall provide updates on a monthly basis and as needed.
		
	 C.     DATA REQUIREMENTS.
	  	TAB-delimited file containing each of the following fields:

  

							
	 Field
	  	Max. Length	  	Required	  	Data Type
	 Supplier_ID*
	  	  9	  	Y	  	Alpha
	 Supplier_Contract #
	  	12	  	N	  	Alpha
	 KPS_Contract #
	  	12	  	Y	  	Alpha
	 Contract_Eftective_Date
	  	10	  	Y	  	MM/DD/CCYY
	 Supplier_Catalog#
	  	30	  	N	  	Alpha
	 Product_Description
	  	90	  	Y	  	Alpha
	 Manufacture_ID*
	  	30	  	Y	  	Alpha
	 Manufacturer_Name
	  	50	  	Y	  	Alpha
	 Manufacturer_Catalog#
	  	30	  	Y	  	Alpha
	 UPC
	  	30	  	N	  	Alpha
	 UPN
	  	30	  	N	  	Alpha
	 NDC
	  	30	  	N	  	Alpha
	 Product_Effective_Date
	  	10	  	N	  	MM/DD/CCYY
	 Product_Expiration_Date
	  	10	  	N	  	MM/DD/CCYY
	 Unit of Measure
	  	  2	  	Y	  	Alpha
	 Unit_Price
	  	    9.3	  	Y	  	Numeric
	 Price_Description
	  	30	  	Y	  	Alpha
	 Pkg_Unit_of_Measure
	  	  2	  	Y	  	Alpha
	 Pkg_Qty_per_Unit
	  	  9	  	Y	  	Numeric

  

	*	HIN (Health Identification Number) or LIC 

  

			
	 D.     FIELD DESCRIPTIONS.
	  	
		
	 Supplier_ID
	  	A code used to identify Supplier. This identifier is used to establish a link to codes used in BroadLink. HIN (Health Industry Identifier) is preferred.
		
	 Supplier_Contract_ID
	  	Supplier’s internal code used to identify the agreement in Supplier’s system for the Product.
		
	 KPS_Contract_ID
	  	KPS contract identifier, assigned by KPS, used to identify the Agreement to Customers.
		
	 Contract_Effective_Date
	  	The Effective Date.
		
	 Supplier_Catalog#
	  	The alphanumeric or numeric identifier assigned by Supplier used to identify the Product.
		
	 Product_Description
	  	Alphanumeric description for the Product.
		
	 Manufacture_ID*
	  	Code used to identify the manufacturer for the specified product. HIN (Health Industry Identifier) is preferred.
		
	 Manufacturer_Name
	  	The name of the manufacturer for the Product.

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	9	  	

			
		
	 Manufacturer_Catalog#
	  	The alphanumeric or numeric identifier assigned by the manufacturer used to identify the specified product.
		
	 UPC
	  	Unit Price Code.
		
	 UPN
	  	Universal Product Number for the Product.
		
	 NDC
	  	National Drug Code.
		
	 Product_Effective_Date
	  	Effective Date.
		
	 Product_Expiration_Date
	  	The expiration date as to which the Product and price is no longer available to Customers.
		
	 Price_Description
	  	Description for the price stated. Used to identify a specific price tier in a multi-tier contract.
		
	 Pkg_Unit_of_Measure
	  	Two-digit unit of measure to identify the packaging contents of the Products unit of measure. For example, a product is available as a case (CA), where it contains four boxes (BX). The box is
the Pkg_Unit_of_Measure.
		
	 Pkg_Qty_per_Unit
	  	Number of packages in the unit of measure. For example, a product is available as a case (CA), where it contains four boxes (BX). The number four is the Pkg_Qty_per_Unit.
		
	 Unit_of_Measure
	  	Two-digit unit of measure for the specified Product.
		
	 Unit_Price
	  	Unit price for the specified Product.
	
	 II.     CROSS-REFERENCE FILE LAYOUT

		
	 A.     REQUIRED FORMAT.
	  	ASCII TAB Delimited file.
		
	 B.     REPORTING FREQUENCY.
	  	Supplier to provide initial cross-reference data at least 30 days prior to the Effective Date and shall provide updates on a monthly basis and as needed.
		
	 C.     REPORTING DATA.
	  	TAB-delimited file containing the following fields:

  

							
	 Field
	  	Max. Length	  	Required	  	Data Type
	 Manufacturer ID*
	  	  9	  	Y	  	Integer
	 UPN
	  	30	  	N	  	Alpha
	 NDC (required for drugs)
	  	30	  	N	  	Alpha
	 Manufacturer Name
	  	50	  	Y	  	Alpha
	 Manufacturer’s Item #
	  	30	  	Y	  	Alpha
	 Product Description
	  	90	  	Y	  	Alpha
	 Manufacturer ID*
	  	  9	  	Y	  	Integer
	 UPN
	  	30	  	N	  	Alpha
	 NDC (required for drugs)
	  	30	  	N	  	Alpha
	 Manufacturer Name
	  	50	  	Y	  	Alpha
	 Manufacturer’s Item #
	  	30	  	Y	  	Alpha
	 Product Description
	  	90	  	Y	  	Alpha

  

	*	HIN # or LIC # preferred 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	10	  	

			
	 III.   PRODUCT ATTRIBUTES FILE LAYOUT

		
	 A.     REQUIRED FORMAT.
	  	ASCII TAB Delimited file
		
	 B.     REPORTING FREQUENCY.
	  	Supplier to provide initial Product attribute data at least 30 days prior to Effective Date and shall provide updates monthly and as needed.
		
	 C.     REPORTING DATA.
	  	TAB-delimited file containing the following fields:

  

							
	 Field
	  	Max. Length	  	Required	  	Data Type
	 Manufacturer ID*
	  	    9	  	Y	  	Integer
	 UPN
	  	  30	  	N	  	Alpha
	 NDC (required for drugs)
	  	  30	  	N	  	Alpha
	 Manufacturer Name
	  	  50	  	Y	  	Alpha
	 Manufacturer’s Item #
	  	  30	  	Y	  	Alpha
	 Attribute Name
	  	  30	  	Y	  	Alpha
	 Attribute Value
	  	256	  	Y	  	Alpha

  

	*	HIN # or LIC # preferred 

  

			
	 IV.   PRODUCT CATEGORIZATION FILE LAYOUT
	  	
		
	 A.     REQUIRED FORMAT.
	  	ASCII TAB Delimited file.
		
	 B.     REPORTING FREQUENCY.
	  	Supplier to provide initial Product categorization data at least 30 days prior to Effective Date and shall provide monthly updates as needed.
		
	 C.     REPORTING DATA.
	  	TAB-delimited file containing the following fields:

  

							
	 Field
	  	Max. Length	  	Required	  	Data Type
	 Manufacturer ID*
	  	  9	  	Y	  	Integer
	 UPN
	  	30	  	N	  	Alpha
	 NDC (required for drugs)
	  	30	  	N	  	Alpha
	 Manufacturer Name
	  	50	  	Y	  	Alpha
	 Manufacturer’s Item #
	  	30	  	Y	  	Alpha
	 Category 1
	  	90	  	Y	  	Alpha
	 Category 2
	  	90	  	N	  	Alpha
	 Category 3
	  	90	  	N	  	Alpha
	 Category 4
	  	90	  	N	  	Alpha
	 Category 5
	  	90	  	N	  	Alpha

  

	*	HIN # or LIC # preferred 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	11	  	

 EXHIBIT C 
 SUPPLIER’S RETURN POLICY 
 For any Product returned to Supplier, Supplier must refund to Customer [***] in
returning the Product to Supplier. Supplier must not charge Customer any restocking fee, shipping fee, handling fee, or any other fee or surcharge relating to Customer’s return of any Product. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	12	  	

 EXHIBIT D 
 SALES DATA REPORT FORMAT 
 A. REQUIRED
FORMAT.                     ASCII Comma Delimited. 
 B. ADDRESS FOR PAYMENT. 
  

			
	 ADMINISTRATIVE FEE PAYMENTS
	  	 REBATE PAYMENTS

	KP Select, Inc.	  	KP Select, Inc.
	P.O. Box 915119	  	P.O. Box 911220
	Dallas, Texas 75391-5119	  	Dallas, Texas 75391-1220
	E-mail: slsrpt@broadlane.com	  	E-mail: slsrpt@broadlane.com
		
	 Overnight Delivery Address
	  	 Overnight Delivery Address

	JP Morgan Chase	  	JP Morgan Chase
	Dallas Wholesale Lockbox Department	  	Dallas Wholesale Lockbox Department
	Maxus Energy Tower	  	Maxus Energy Tower
	717 North Harwood Street, 6th Floor	  	717 North Harwood Street, 6th Floor
	Dallas, Texas 75201-6507	  	Dallas, Texas 75201-6507
	Attn: KP Select, Inc., Lockbox 915119	  	Attn: KP Select, Inc., Lockbox 911220
		
	 Wire Transfer
	  	 Wire Transfer

	KP Select, Inc.	  	KP Select, Inc.
	JP Morgan Chase	  	JP Morgan Chase
	Account # 	  	Account # 
	ABA #	  	ABA #
	Reference: (Admin. Fee, Contract Number, Payment Period)	  	Reference: (Rebate, Contract Number, Payment Period)

 Any rebates that are paid directly by Supplier to Customers will continue to be paid directly to the Customers.

 C. REPORTING DATA.                
    Comma-delimited file containing the following fields: 
  

									
	 Field
	  	Max. Length	  	Required	  	Data Type	  	Sample Data
	 Supplier Internal Acct #
	  		  		  		  	
	 (assigned to Customer)
	  	12  	  	Y	  	Alpha	  	414620J00 or ABBOTT
	 Facility ID*
	  	12  	  	Y	  	Alpha	  	212840H00
	 Facility Name
	  	50  	  	Y	  	Alpha	  	Memorial Med. Center
	 Address
	  	35  	  	Y	  	Alpha	  	123 Main Street
	 City
	  	15  	  	Y	  	Alpha	  	Dallas
	 State
	  	2  	  	Y	  	Alpha	  	TX
	 Zip
	  	10  	  	Y	  	Alpha	  	75218
	 KPS Contract #
	  	12  	  	Y	  	Alpha	  	GA-001
	 Supplier Contract #
	  	12  	  	N	  	Alpha	  	TEN01
	 Sales Month** Begin Date
	  	10  	  	Y	  	MM/DD/YYYY	  	01/01/2004
	 Sales Month** End Date
	  	10  	  	Y	  	MM/DD/YYYY	  	01/31/2004
	 Total Sales (dollars)
	  	9.3	  	Y	  	Numeric	  	20000.00
	 Total Fee
	  	9.3	  	Y	  	Numeric	  	600.00

  

	*	HIN (Health identification Number) or DEA number preferred. 

  

	**	Quarterly reporting must include sales detail by month 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	13	  	

 EXHIBIT E 
 KPS STANDARD TERMS AND CONDITIONS 
 I. DEFINITIONS 
 Any capitalized terms that are not defined in this exhibit have the meanings set forth in the document into which this exhibit is incorporated (this
“Agreement”). 
 II. REGULATORY MATTERS 
 A. Safe Harbor. Supplier shall comply with the applicable requirements of the “Discount” safe-harbor to the Federal Anti-Kickback Statute (42 U.S.C. §1320 a-7b, as amended) set forth in 42 C.F.R. 1001.952(h).

 B. Federal Program Participation. The Office of Inspector General (“OIG”) Special Advisory Bulletin on the Effect or Exclusions on
Participation in Federal Health Care Programs clarifies the OlG’s sanction authority to impose civil money penalties and deny reimbursement under federal health care programs of any and all products or services if products or services are
provided by an excluded entity. (Federal Register, September 30, 1999, Vol. 64, No. 189, pp. 52791-52794.) The OIG Special Advisory Bulletin specifically provides that “items or equipment sold by an excluded manufacturer or supplier
used in the care or treatment of beneficiaries and reimbursed, directly or indirectly, by a federal health care program violate the OlG’s exclusion.” Supplier represents and warrants that neither it, nor any of its key personnel, have been
convicted of an offense related to health care or listed by a federal agency as being debarred, excluded, or otherwise ineligible for federal program participation as of the Effective Date and that Supplier shall immediately notify KPS and Customers
in writing if any of these events occurs. 
 C. HIPAA. This Agreement and certain data that may be exchanged under this Agreement may be subject to
(i) the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and Supplier may be
considered a “business associate” of Customer for purposes of HIPAA and the rules and regulations promulgated under HIPAA and (ii) the Confidentiality of Medical Information Act (California Civil Code Sections 56.10 et seq,)
(the “Medical Information Act”). If Customer determines that Supplier must agree to additional terms to comply with HIPAA, the Medical Information Act, or any other privacy law or regulation, Supplier will agree with Customer to those
terms. If Customer and Supplier do not reach agreement, Customer may terminate its participation under this Agreement. 
 D. Equal Opportunity. Some
Customers are government contractors and are subject to various federal laws, executive orders and regulations regarding equal opportunity, and affirmative action (“Requirements”). Some suppliers and subcontractors who contract with these
Customers also must comply with these Requirements. KPS notifies Supplier that Supplier may be subject to certain Requirements and incorporates by reference the following clauses from the Federal Acquisition Regulation (FAR) at 48 C.F.R, pt. 52:
(a) Equal Opportunity (Feb. 1999) at FAR 52.222-26; (b) Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and other Eligible Veterans (Dec. 2001) at FAR 52.222-35; (c) Affirmative Action for Workers with
Disabilities (June 1998) at FAR 52.222-36; and (d) Small Business Subcontracting Plan (Oct. 1999) at FAR 52.219-9. 
 E. Safe Medical Devices
Act. Supplier must notify Customer, in writing and on a quarterly basis, of any reports regarding any Product filed under the Safe Medical Devices Act of 1990 (21 U.S.C. § 301, et al.) or any other federal product safety reporting
requirement. 
 III. AUDIT RIGHTS 
 A.
KPS Audit of Supplier. No more than once every 12 months, Supplier shall permit KPS or an independent auditor appointed by KPS to conduct an audit of Supplier’s books and records relating to orders, invoices, sales reports, and discounts,
for the sole purpose of determining whether the correct pricing has been extended to Customers and the correct Administrative Fees, service fees, or other amounts due to KPS and the Customers have been paid. The audits must be conducted upon
reasonable advance notice during the regular business hours at Supplier’s principal office and in a manner not to interfere unduly with Supplier’s operations. If any audit of Supplier’s invoices or other records reveals any variance
from any invoice to any Customer, Supplier shall immediately refund any excess payment received from the Customer. In addition, if any audit reveals any variance from any invoice in excess of 5% of the amount shown on the invoice, or an underpayment
of Administrative Fees or service fees by more than 5%, Supplier shall reimburse KPS for all costs and expenses incurred in conducting the audit. 
 B.
Customer Audit of Supplier. Throughout the Term, Supplier shall permit any Customer or its third-party auditor to conduct an audit of Supplier’s books and records relating to orders, invoices, sales reports, and discounts for the sole
purpose of verifying correct pricing (including proper rebates) to that Customer. The audits must be conducted upon reasonable advance notice during the regular business hours at Supplier’s principal office and in a manner not to 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	14	  	

 
interfere unduly with Supplier’s operations. If any audit of Supplier’s invoices or other records reveals any variance from the invoices of the
Customer initiating the audit. Supplier shall immediately refund any excess payment received from the Customer. In addition, if any audit reveals an aggregate variance from the invoices in excess of 5% of the amount shown on the invoices, then
Supplier shall reimburse the Customer for all costs and expenses incurred in conducting the audit. 
 C. Statutory Audit Rights for Services.

 1. Supplier shall, upon five days’ prior written request, grant to the Secretary of the Department of Health and Human Services
(the “Secretary”), the Secretary’s duly-authorized representative, the Comptroller General of the United States, or the Comptroller General’s duly-authorized representative, right to review any and all books, documents, and
records as may be necessary to certify the nature and extent of the costs of the services in excess of $10,000 per year. 
 2. If any of the
services are performed by way of subcontract with another organization, the subcontract must contain and Supplier shall enforce a clause to the same effect as in Section III.C.1 above. 
 3. This provision survives the expiration or other termination of this Agreement, regardless of the cause giving rise to the expiration or termination.

 IV. CONFIDENTIALITY 
 A. Protection
of Customer’s Information. Supplier shall not in any manner disclose any information relating to the purchases by Customers of Products or purchases except to the Customer or KPS, and KPS shall not in any manner disclose pricing of
Products, except to Customers. 
 B. Agreement Confidential. Neither party to this Agreement may disclose the terms of this Agreement to any other
person or entity other than a Customer or as required by law. Neither party may make any public announcement concerning the existence of this Agreement or its terms without the prior written approval of the other party. KPS is entitled to disclose
relevant information to potential Customers for the purpose of demonstrating Product availability or cost savings to the potential Customer. 
 C.
Survival. The terms of this confidentiality provision survive any termination or expiration of this Agreement. 
 V. INDEMNIFICATION

 A. Indemnification of Customers. Supplier shall indemnify, defend, and hold each Customer and its affiliates, officers, directors, and agents
harmless from and against all damages, claims, or other losses arising from a breach of this Agreement by Supplier or arising from Products. This indemnity must include provision of a defense to any third party claims and the advance of costs
related to this defense but does not extend to any portion of the loss due to a Customer’s negligence or willful misconduct. 
 B. Indemnification of
KPS. Supplier shall indemnify, defend, and hold KPS and its affiliates, officers, directors, and agents harmless from and against all damages, claims, or other losses arising from a breach of this Agreement by Supplier or arising from Products.
This indemnity must include provision of a defense to any third party claims and the advance of costs related to this defense but does not extend to any portion of the loss due to KPS’ negligence or willful misconduct. 
 C. Indemnification of Supplier. KPS shall indemnify, defend, and hold Supplier and its affiliates, officers, directors, and agents harmless from and against all
damages, claims, or losses caused by KPS’ breach of any term in this Agreement. This indemnity must include provision of a defense to any third party claims and the advance of costs related to this defense but does not extend to any portion of
the loss due to Supplier’s negligence or willful misconduct. 
 VI. WARRANTIES 
 A. Product Warranties. The warranty for each Product purchased pursuant to this Agreement is set forth in Exhibit G to this Agreement. 
 B. Services Warranty. Supplier represents and warrants that its employees, agents, and representatives have the skills and qualifications necessary to perform
services under this Agreement in a timely, competent, first class, and professional manner in accordance with the highest industry standards and all applicable governmental requirements, laws, ordinances, rules, and regulations, and that Supplier is
able to fulfill the technical service requirements and all other services requirements of this Agreement. 
 C. Manufacturers’ Warranties.
Supplier shall provide to KPS copies of all warranties for Products Supplier receives from its vendors and all manufacturers’ warranties. Supplier assigns to KPS and to the Customers all vendors’ and manufacturers’ warranties and
rights of action under these warranties and authorizes KPS and Customers to enforce these warranties. 
 D. Warranties Cumulative. The warranties
provided under this Agreement are cumulative and apply to any replacement or modification of Products by Supplier or its employees, agent or agents, or 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	15	  	

 
representatives, and these warranties are in addition to any warranties provided at law or in equity. 
 VII. MISCELLANEOUS 
 A. Governing Law and Venue.
This Agreement must be construed and its performance enforced under Texas law. The parties agree to be subject to personal jurisdiction in and consent to service of process in the State of Texas, except where an individual suit may involve
Supplier and a Customer, in which case Supplier consents to the personal jurisdiction and service of process in the state or commonwealth where the Customer is domiciled. This Section survives expiration or other termination of this Agreement.

 B. Third Party Beneficiary. This Agreement is entered into by KPS for the express, intended benefit of Customers and KPS, Each Customer is
an intended third party beneficiary of this Agreement. Each Customer may enforce the terms and provisions of this Agreement that affect that Customer. 
 C. Binding Effect Upon Successors. This Agreement is binding upon and inures to the benefit of the parties and their respective successors and permitted assigns. 
 D. Assignment. Neither party may assign, subcontract, delegate, or otherwise transfer this Agreement or any of its rights or obligations under this Agreement (other than to a subsidiary or parent company of a
party owning greater than 50% of that party) nor may it contract with third parties to perform any of its obligations. 
 E. No Waiver.
The waiver of any breach of any term or condition of this Agreement does not waive any other breach of that term or condition or of any other term or condition unless agreed to in a writing signed by both parties. 
 F. Severability. If any part of this Agreement is for any reason found to be unenforceable, the unenforceable provision is reformed to conform to the law and all
other parts of this Agreement nevertheless remain enforceable. 
 G. Headings. The descriptive headings of the sections of this Agreement are inserted
for convenience only and do not control or affect the meaning or construction of any section. 
 H. Notices. Any notice required to be given under
this Agreement must be in writing, postage and delivery charges pre-paid, and may be sent by fax, hand delivery, overnight mail service, first-class mail, or certified mail with return receipt requested to KPS or Supplier at the addresses and fax
numbers set forth below. Any party may change the address to which notices are to be sent by notice given in accordance with the provisions of this Section. Notices under this Agreement are deemed to have been given, and are effective upon, actual
receipt by the other party or, if mailed, upon the earlier of the fifth day after mailing or actual receipt by the other party. 
  

			
	If to KPS:	  	 KP Select, Inc.
 13727 Noel Road, Suite
1400
 Dallas, Texas 75240
 Attn: Custom Contracting
 Fax: 972.813.7893

		
	And:	  	 KP Select, Inc.
 13727 Noel Road, Suite
1400
 Dallas, Texas 75240
 Attn: Operations Counsel
 Fax: 972.813.7939

		
	If to Supplier:	  	 SenoRx, Inc.
 11 Columbia
 Aliso Viejo, California 92656
 Attn: William F. Gearhart
            VP, Sales & Marketing
 Fax: 949.362.3519

 I. Publicity. Supplier may not, without the prior written consent of KPS, use in advertising, publicity, or
otherwise the names, trade names, trademarks, service marks, trade dress, or logos of KP Select, Inc., KPS, and KPS Customers, or refer to the existence of this Agreement in any press releases, advertising, or materials distributed to prospective
customers or other third parties. 
  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	16	  	

 EXHIBIT F 
 STANDARD TERMS AND CONDITIONS — PRODUCTS AND PRODUCT SYSTEMS 
 I. REQUIREMENTS 

A. Replacement Products. If Supplier discontinues any Product and fails to provide a substitute of comparable functionality
at a price not higher than the discontinued Product, the commitment requirements set forth in the Agreement, if any, shall not apply and Customer may purchase a substitute from any source. 
 B. Special Promotional Pricing. If Supplier offers a special promotion, it must be offered to all Customers and limited to the terms and conditions of the
specific promotion. Supplier shall give KPS at least 14 days advance written notice of special promotions and coordinate all special promotions through KPS. If Supplier fails to follow this procedure, then any special promotional pricing more
favorable than the prices offered to Customers under this Agreement becomes the new net pricing under this Agreement and applies for the remaining Term. If new net pricing goes into effect under this provision, the parties shall amend Exhibit
A incorporating the new pricing. 
 C. Representatives. Supplier shall respond within 24 hours of a Customer’s request for a Supplier
representative (including Customer’s request for training or service to Product System). Supplier must comply with Customer’s current visitation policies. 
 D. Product Notices. Supplier shall send all notices relating to the Products, as well as notices of any other changes affecting the Product and notices of new Product, to each Customer with copies to
KPS. Supplier shall send written notice to all Customers and KPS not more than 24 hours after Supplier learns of any Product notice that may adversely affect the health or well being of any user of Product. 
 E. Product Recalls. Supplier shall notify KPS and all Customers of any Product recalls not more than 24 hours after Supplier first learns of the recall,
and Supplier shall use its best efforts to monitor the recall status of all Products. Notices must include instructions and information regarding the Product recall and appropriate action to be taken by Customers. All costs associated with the
correction of the recall and actions taken in response to the recall must be borne by Supplier. 
 F. New Technology. 
 1. Off Contract. If, during the Term, new technology (meaning more than an enhancement or improvement to an existing Product) for a Product
becomes available from any source, including Supplier, that (i) offers significant technological advancements, (ii) would significantly improve clinical outcomes, or (iii) would significantly streamline work processes, as compared to
existing Products (“New Technology”), then the commitment requirements set forth in the Agreement, if any, do not apply and KPS has the right to evaluate and contract with another Supplier so Customers have access to New Technology at all
times. If Supplier cannot offer New Technology at comparable prices, the commitment requirements set forth in the Agreement, if any, do not apply and KPS has the right to contract with other suppliers for New Technology. 
 2. Add to Contract. Supplier shall give Customers priority access to new product releases. At least twice per year, Supplier must provide an
update to Customer regarding Supplier’s business, including any new product releases and New Technology to be offered by Supplier. If Supplier offers New Technology at comparable discounts, then with KPS’ approval, Supplier must amend the
Products and pricing on Exhibit A to include the New Technology. 
 G. Obsolete Technology. If KPS determines in its sole discretion
that the technology of any Product falls behind current industry standards, KPS may contract with another source for appropriate products after giving Supplier 30 days’ written notice. Obsolete Products are automatically deleted from Exhibit
A after KPS’ notice to Supplier. 
 H. Authorized Distributors. The following distributors are authorized by KPS to distribute the
Products: Owens & Minor, and Caligor; and for alternate sites, PSS, McKesson, and Henry Shein. 
 I. HCPCS Codes for Medicare Reporting.
Supplier must provide to Customers all HCPCS Codes recognized by Medicare for all Products and must cross-reference each HCPCS Code by Supplier’s Name, Supplier’s Identification Number, and Supplier’s Product Catalog Number. At any
Customer’s request, Supplier must also provide HCPCS Codes for anything Supplier sold to that Customer since August 1, 2000. Regardless of any commitment level a Customer may enter into with Supplier under this Agreement. The Customer has
no duty to purchase a Product for which Supplier does not comply with this Section. If a Customer has a commitment obligation, the obligation is decreased to the extent a Customer does not buy Products for which Supplier does not comply with this
provision. In addition to all other remedies, KPS may terminate this Agreement if Supplier does not comply with this provision. 
  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	17	  	

 J. Electrical Requirements. Supplier represents and warrants that all electrical Products are UL-approved or
CSA-approverd. 
 II. PURCHASING TERMS AND CONDITIONS 
 A. Order Cancellation. Except orders for any custom Product System, which may not be canceled without Supplier’s approval, Customers may cancel orders at any time before Supplier’s shipment of the
applicable Product System, with no cost or penalty. 
 B. Product System Site Preparation. Customer, at its expense, shall prepare the clinical sites
where Product System will be installed according to the site preparation recommendations of Supplier. In no event is Supplier responsible for the quality or adequacy of the work not performed by, or not under the authority of, Supplier. 

C. Installation Schedule. Supplier must cooperate with the Customer to schedule installation of each Product System at a time when the installation would have
minimal impact on the Customer’s business operations. Supplier may not schedule any installation of any Product System without first obtaining the Customer’s approval of the proposed installation schedule. The proposed installation
schedule that Supplier must present to Customer for Customer’s approval must include an estimate of the time required to complete installation and testing of the Product System, and the time required to complete clinical training on the Product
System. 
 D. Preparation for Installation of Product System. After delivering Product System, and at no additional charge, Supplier is fully
responsible for performing all tasks necessary to install the Product System, including, without limitation, uncrating, unpacking, field assembly, interconnection, calibration, testing, and inspection, to ensure that the Product System conforms to
Product System specifications and is completely ready to perform all procedures for which it is designed and marketed by Supplier. 
 E. Inspection and
Acceptance. 
 1. Product System not Requiring Installation by Supplier. For Product System that is not installed by Supplier,
Customer has ten business days from the date of delivery to inspect and accept or reject the Product System. If Customer finds the Product System is broken or damaged, then Customer may reject the Product System and return it at Supplier’s
expense. This provision does not limit Customer’s remedies. 
 2. Product System Requiring Installation by Supplier. For Product
System that is installed by Supplier, Customer is not deemed to have accepted any Product System until the Product System is operating according to specifications and ready for use. 
 F. Returns. If these terms conflict with Supplier’s return policy attached as Exhibit C, these return terms control. 
 1. Reasons for Returns. Customer may return Product System to Supplier, at Customer’s option, if Customer determines in good faith that any of the following conditions are met: 
 a. Product System is shipped in error by Supplier; 
 b. Product System is damaged before it is accepted by Customer; 
 c. Product System’s packaging or crating is damaged before it is accepted by Customer; 
 d. Product System does not materially perform to performance specifications provided by Supplier or the manufacturer of Product System;

 e. Product System does not meet industry quality standards related to performance specifications and data submissions
required by the FDA or FDA approval of the Product System; 
 f. Supplier gives prior written approval and Supplier shall not
unreasonably withhold its approval. 
 2. Manner of Return. Where possible, Customer shall return Product System in its original
packaging or crating. 
 III. TRAINING, WARRANTY, AND AFTER- 
 WARRANTY MAINTENANCE 
 A. Training. At no additional charge, Supplier shall perform, at a
time and location reasonably requested by Customer (including all three work shifts, if necessary in Customer’s sole judgment), in-service, clinical, applications, and biomed training sessions for Customer’s personnel (including nurses,
physicians, and technologists). Supplier must provide each Customer with a detailed written description of this training, including a description of the program length and format, program content, qualifications of instructors, and any written
materials to be distributed, and must also include Supplier’s recommendation regarding the frequency of refresher courses. Supplier must provide sufficient samples to Customer to accomplish this and any other Product training undertaken by the
Customer, but Supplier must not provide any more samples than is necessary to 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	18	  	

 
accomplish the Customer’s training needs. If Supplier offers e-training, Supplier must also make e-training available to each Customer at no additional
charge. If requested by Customer, Supplier must certify that the trained personnel have completed Supplier’s training program. 
 B. Training
Materials. At no additional charge, Supplier must provide a written training guide or set of training videotapes to each Customer to be used for in-service training by Customer’s staff. Customers are entitled to make copies, for internal
purposes only, of any in-service and clinical training materials. 
 C. Biomed Orientation. At no additional charge, if requested by a Customer,
Supplier shall provide Customer’s biomed staff with an on-site orientation and in-service session upon installation of Product System. If Customer coordinates a location and training agenda with 10 or more biomed personnel, Supplier shall
provide training at the agreed upon location at no charge. 
 D. Manuals. At no additional charge, Supplier shall supply Customers with the following
items no later than the time of delivery of the Product System: (i) two copies of operator manuals covering the applicable Product System and accessories; and (ii) one copy of complete service manuals detailing applicable Product System
and accessories including, but not limited to, parts lists and diagrams. All updates to manuals and final versions (where applicable) of manuals must be provided for the life of the Product System. The duty to provide updates under this provision
survives the expiration or other termination of this Agreement. 
 E. Warranty Extension. If any Product System exceeds generally accepted repair down
time during the warranty period, Supplier shall extend the warranty coverage on the affected Product System for no additional charge until the Customer is fully satisfied with the performance of the Product System. 
 F. Product System Maintenance. Supplier warrants that it is possible for the Product System to be maintained during its useful life by Customer to
manufacturer’s specification without an after-warranty maintenance contract. 
 G. Maintenance Discounts. Supplier shall provide discounts for
after-warranty Product System maintenance, including repair labor, travel charges, Product System software, and replacement parts. These discounts are listed on Exhibit A. 
 H. Copies of Maintenance Contracts. If requested by KPS, Supplier shall mail copies of all maintenance contract proposals for Customers, attention: Equipment Contracting Department, at the same time the
maintenance contracts are offered to Customers. 
 I. Independent Service Organization. If requested, Supplier shall sell maintenance services to
Independent Service Organizations (“ISO”) that are designated as third party agents of Customers. 
 J. Product Enhancements and Upgrades.
During the useful life of the applicable Product, Supplier must provide all Product enhancements and upgrades (including Product System software upgrade) to Customer at a price [***], and within [***] of Supplier’s notification to Customer of
the release of the enhancement or upgrade. Included in the price of each software upgrade is one kit Product so that Customer may confirm the upgrade. For the avoidance of doubt, Supplier’s provision of Product enhancements and upgrades is not
conditioned upon Customer’s purchase of a maintenance agreement, warranty, or extended warranty. This provision survives expiration or other termination of this Agreement. 
 K. Enhancement and Upgrade Notification. For each Product purchased by Customer, Supplier must notify the Customer of each Product enhancement and upgrade (including Product System software upgrades and any
hardware upgrade associated with the software upgrade), within 30 days of Supplier’s release of the upgrade. 
 L. Scheduling Product System
Upgrades. Supplier must cooperate with the Customer to schedule any installation of software upgrade (and any associated hardware upgrade) at a time when the installation would have minimal impact on the Customer’s business operations.
Supplier may not schedule any installation of any software upgrade without first obtaining the Customer’s approval of the proposed installation schedule. 
 IV. MISCELLANEOUS 
 A. Supplier Representatives. Supplier shall provide representatives to call upon Customers
on a periodic basis as agreed by Supplier and the respective Customers. Supplier’s representative shall respond to Customer’s demand for a call not more than 24 hours after Customer’s demand to Supplier. Supplier (including
Supplier’s representatives) must comply with each Customer’s vendor-visitation policies. 
 B. Product System Recalls. Supplier shall notify
KPS and all Customers of any Product System recalls not more than 24 hours after Supplier first learns of the recall, and Supplier shall use its best efforts to monitor the recall status of all Product System. Notices must include instructions and
information regarding the Product System recall and appropriate action to be taken by Customers. All costs associated with the correction of the recall and actions taken in response to the recall must be borne by Supplier. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	19	  	

 C. Product System Notices. Supplier shall send all notices relating to the Product System, as well as notices of
any other changes affecting the Product System and notices of new Product System, to each Customer with copies to KPS. Supplier shall send written notice to all Customers and KPS not more than 24 hours after Supplier learns of any Product System
notice that may adversely affect the health or well being of any user of Product System. 
 D. Accessories. Supplier shall offer Product System
accessories and components to Customers, including, but not limited to, hardware, firmware, and software that may be used with Product System. This duty survives the expiration or other termination of this Agreement. 
 E. Replacement Parts. All replacement parts for the Product System must be available for not less than ten years following the earlier of either (i) the date
when Supplier ceases to sell the Product System or a reasonable substitute of the Product System, or (ii) the expiration of the warranty period described in this Agreement, including all applicable warranty extensions. 
  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	20	  	

 EXHIBIT G 
 SUPPLIER’S PRODUCT WARRANTIES 
 1. Consumable Products. Supplier warrants that all consumable Products
are free from defects in material and workmanship, meet Product specifications set forth in the Product packaging. This warranty is in addition to any warranties provided by law. 
 2. Reusable Products. Supplier warrants that all non-consumable Products (e.g., Product Systems) are free from defects in material and workmanship, meet Product specifications set forth in the Product
packaging. This warranty is in addition to any warranties provided by law. 
 In addition, Supplier warrants that all non-consumable Products
function as designed and represented for a period of eighteen months after Customer’s first use of the Product (“Initial Warranty Period”). This is a “no-fault” warranty, meaning that it applies to all non-consumable
Products except those non-consumable Products damaged by Customer’s alteration, modification, or abuse, or otherwise damaged by vandalism, burglary, or theft while in Customer’s custody and control. 
 3. Uptime Guarantee and Maintenance Agreements. After the Initial Warranty Period, Customers may purchase maintenance agreements at the prices listed on
Exhibit A. Those maintenance agreements provide warranty protection for the non-consumable Products as if the Products were within the Initial Warranty Period. 
 4. Warranty Remedy. Customer’s sole remedy under this warranty is that Supplier must repair or replace the non-conforming Product (at Customer’s discretion) within 24 hours after Customer notifies
Supplier of the problem. Nothing in this warranty limits any of Customer’s other rights or remedies. 
 IN NO EVENT SHALL THE SUPPLIER BE LIABLE TO THE
CUSTOMER OR ANY THIRD PARTY FOR LOST PROFITS, OR ANY SPECIAL CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES FOR BREACH OF THIS WARRANTY. THIS LIMITATION SHALL APPLY EVEN WHERE THE SUPPLIER HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE AND
NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY STATED HEREIN. 
  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	21	  	

 EXHIBIT H 
 SUPPLIER’S ENVIRONMENTAL AND SOCIAL ISSUES DISCLOSURES 
 Mercury Reduction. KPS’ key Customers are
committed to minimizing the amount of mercury used in their operation and desire to avoid the acquisition of Products that contain mercury whenever feasible alternatives exist that do not compromise patient care. Supplier must provide information in
relation to those Products that contain mercury. 
  

	x	The Products do not contain mercury. 

  

	 ̈	The Products that contain mercury are identified in Exhibit A to this Agreement, which specifies the amount of mercury contained in each product that contains mercury and
indicates if a feasible mercury-free alternative is available. 

 Latex Reduction. KPS’ key Customers are committed to protecting
patients and healthcare workers against exposure to latex and its allergenic properties. Supplier must provide information in relation to those Products that contain latex either in the Products or their packaging. 
  

	x	The Products or their packaging offered in this Agreement do not contain latex. 

  

	 ̈	The Products or their packaging that contain latex are identified in Exhibit A to this Agreement which specifies the location of latex contained in each product or its
packaging. 

 Hazardous Substances or Processes. Supplier will deliver to KPS and Customers a Material Safety Data Sheet (MSDS) for each
hazardous substance or mixture as defined in any local, state, or federal statute, law, or code ordered under the agreement. Each MSDS must contain all required information concerning the hazardous substance or mixture, in a format agreed upon by
KPS or the Customer. 
 Environmental Conditions. Supplier will notify KPS and Customers of any environmental conditions (such as storage
temperature), limitations, or requirements for use and storage of the Products. 
 Social Issues: (attached) 
  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	22	  	

 EXHIBIT I 
 QUALITY ASSESSMENT AND IMPROVEMENT PROGRAMS 
 A. KFHP Quality Assessment and Improvement Programs. Supplier
hereby acknowledges that the quality assessment and improvement programs of KFHP require KFHP to monitor the quality assessment and improvement activities of contracting providers. Supplier agrees (i) to participate in KFHP’s quality
assessment and improvement programs, including review by KFHP’s quality assurance and improvement committees and staff, (ii) to abide by KFHP’s quality assessment and improvement plans, and (iii) to cooperate with KFHP to
objectively monitor and evaluate the quality or services provided at Supplier’s site(s), including, but not limited to, the availability, accessibility, acceptability, and continuity of such care. 
 Supplier shall investigate and respond immediately to all quality issues, and shall work with KFHP to resolve any accessibility and other quality issues related to
services provided to KFHP patients. Supplier will remedy, as soon as reasonably possible, any condition related to patient care which has been determined by KFHP, or any government or accrediting agency to be unsatisfactory. The parties shall work
together to continuously assess and improve the quality and accessibility of care provided to KFHP patients and to resolve problems related to the provision of services. 
 Supplier will provide information for use in quality assessment and improvement activities conducted by KFHP, including, but not limited to, Customer and patient specific information. KFHP will protect the
confidentiality of such information to the extent required under state and federal law. Upon request, Supplier shall provide data, information and records (i) which KFHP must review for accreditation by the National Commission for Quality
Assurance (“NCQA”) and for credentialing activities that meet NCQA standards, and (ii) which is required by other accrediting organizations. Supplier will provide KFHP access to all patient care protocols, policies and procedures, and
any modifications, upon request. 
 Supplier shall permit, at reasonable times with reasonable notice, Inspection of its site(s) by accrediting
organizations. Supplier shall permit KFHP and appropriate government officials to conduct periodic site evaluations of Supplier’s site(s). Supplier will participate in all utilization management, quality assessment and improvement,
credentialing, re-credentialing, peer review, and any other activities required by regulatory and accrediting agencies. 
 KFHP’s duty hereunder does
not relieve Supplier of any duty of care to provide KFHP patients with services in accord with the appropriate standard of care. 
 B. KFHP Compliance
with Laws. KFHP shall ensure, through its quality assessment and improvement programs, that services performed by Supplier under this Agreement at a KFHP facility are performed in a safe and effective manner, as required by 42 Code of Federal
Regulations Section 482.12(e), and KFHP shall retain administrative and professional responsibility for all services rendered by Supplier to patients of KFHP, as required by Title 22 California Code of Regulations Section 70713. The
foregoing shall not modify the allocation of liability or indemnification obligations between the parties as set forth in this Agreement or as otherwise provided by law. 
 Supplier agrees to comply with applicable law regulation in the performance of services to KFHP patients. To the extent Supplier provides services in support of any KFHP entity accredited by the Joint Commission on
Accreditation of Healthcare Organizations (JCAHO), Supplier agrees to provide services in accord with applicable JCAHO standards. 
  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	23	  	

 EXHIBIT J 
 CONTRACT IMPLEMENTATION PLAN 
 Supplier Training Program: 
  

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

 Contract Implementation –
will be based on implementation schedule to be provided by Customer: 
  

	 	1.	Installation appointments scheduled with each Customer breast center facility based on availability of staff for biopsy Product System installation training.

  

	 	2.	[***] 

  

	 	3.	Clinical application specialists assigned to each Customer breast center for on-going training and in-servicing needs. 

  

	 	4.	Total number of breast canters installed will be based upon implementation schedule provided by Customer and could include up to [***] locations every 30 days.

 Implementation schedule for any additional locations and new units that are added will be based on schedule provided by Customer.

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	24	  	

 EXHIBIT K 
 MAINTENANCE POLICY 
 If the Product is not under warranty, Customer may purchase Major Repair services or Minor
Repair services for the Product at the prices set forth on Exhibit A. For the avoidance of doubt, the pricing on Exhibit A for all repair services includes shipping to and from the Customer and an appropriate shipping container for the
Product being shipped. 
 The following are Major Repairs: 
  

	 	[***]	

 All other repairs are Minor Repairs. All Minor Repairs entail;

  

	 	•	 	Complete functional test 

  

	 	•	 	Complete safety test 

 Examples of Minor Repairs include; 
  

	 	[***]	

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	25	  	

 EXHIBIT L 
 TRADE-IN ALLOWANCES 
 Supplier must provide a $[***] trade-in value for each piece of competitive equipment at a
particular Customer’s location, if Customer does not have competitive equipment at a location, then Supplier must provide a $[***] discount on the first Product System the Customer purchases for that location. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	 SenoRx, Inc.
 Agreement for Breast Biopsy
Products
 Version 3-11-04 (Rev. 2/17/05)
	  	26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]